METHOD FOR MAKING HUMANIZED ANTIBODIES

Abstract: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

Description: METHOD FOR MAKING--HUMANIZED ANTIBODIES. Field of the Invention This invention relates to methods for the preparation and use of variant antibodies a finds application particularly in the fields of immunology and cancer diagnosis and therap Background of the Invention Naturally occurring antibodies (immunoglobulins) comprise two heavy chains link together by disulfide bonds and two light chains, one light chain being linked to each of t heavy chains by disulfide bonds. Each heavy chain has at one end a variable domain ( followed by a number of constant domains. Each light chain has a variable domain (V L ) at o end and a constant domain at its other end; the constant domain of the light chain is align with the first constant domain of the heavy chain, and the light chain variable domain aligned with the variable domain of the heavy chain. Particular amino acid residues a believed to form an interface between the light and heavy chain variable domains, see e. Chothia et al., J. Mo/. Bio/. 186:651 -663 (1985); Novotny and Haber, Proc. Natl. Acad. S USA 82:4592-4596 (1985). The constant domains are not involved directly in binding the antibody to an antige but are involved in various effector functions, such as participation of the antibody in antibod dependent cellular cytotoxicity. The variable domains of each pair of light and heavy chai are involved directly in binding the antibody to the antigen. The domains of natural light a heavy chains have the same general structure, and each domain comprises four framewo (FR) regions, whose sequences are somewhat conserved, connected by three hyper-variab or complementarity determining regions (CDRs) (see Kabat, E. A. etal., Sequences of Protei of Immunological Interest, National Institutes of Health, Bethesda, D, (1987)). The fo framework regions largely adopt a ff-sheet conformation and the CDRs form loops connectin and in some cases forming part of, the /?-sheet structure. The CDRs in each chain are held close proximity by the framework regions and, with the CDRs from the other chain, contribu to the formation of the antigen binding site. Widespread use has been made of monoclonal antibodies, particularly those deriv from rodents including mice, however they are frequently antigenic in human clinical use. F example, a major limitation in the clinical use of rodent monoclonal antibodies is anti-globulin response during therapy (Miller, R. A. etal.. Blood 62:988-995 (1983); Schro R. W. et al., Cancer Res. 45:879-885 (1985)). The art has attempted to overcome this problem by constructing "chimeric" antibodi in which an animal antigen-binding variable domain is coupled to a human constant doma (Cabilly etal., U.S. patent No. 4,816,567; Morrison, S. L. etal., Proc. Natl. Acad. Set. U 81 :6851-6855 (1984); Boulianne, G. L etal., Nature 312:643-646 (1984); Neuberger, M. etal.. Nature 314:268-270 (1985)). The term "chimeric" antibody is used herein to descri a polypeptide comprising at least the antigen binding portion of an antibody molecule link to at least part of another protein (typically an immunoglobulin constant domain). The isotype of the human constant domain may be selected to tailor the chimeri antibody for participation in antibody-dependent cellular cytotoxicity (ADCC) an complement-dependent cytotoxicity (see e.g. Brϋggemann, M. et al., J. Exp. Me 166:1351 -1361 (1987); Riechmann, L. et al.. Nature 332:323-327 (1988); Love et al Methods in Enzymology 178:515-527 (1989); Bindon et al., J. Exp. Med. 168:127-14 (1988). In the typical embodiment, such chimeric antibodies contain about one third rodent ( other non-human species) sequence and thus are capable of eliciting a significant anti-globuli response in humans. For example, in the case of the murine anti-CD3 antibody, OKT3, muc of the resulting anti-globulin response is directed against the variable region rather than th constant region (Jaffers, G. J. et al., Transplantation 41 :572-578 (1986)). In a further effort to resolve the antigen binding functions of antibodies and to minimiz the use of heterologous sequences in human antibodies. Winter and colleagues (Jones, P. et al., Nature 321 :522-525 (1986); Riechmann, L. et al., Nature 332:323-327 (1988) Verhoeyen, M. etal., Science 239:1534-1536 (1988)) have substituted rodent CDRs or CD sequences for the corresponding segments of a human antibody. As used herein, the ter "humanized" antibody is an embodiment of chimeric antibodies wherein substantially less tha an intact human variable domain has been substituted by the corresponding sequence from non-human species. In practice, humanized antibodies are typically human antibodies in whic some CDR residues and possibly some FR residues are substituted by residues from analogou sites in rodent antibodies. The therapeutic promise of this approach is supported by the clinical efficacy of humanized antibody specific for the CAMPATH-1 antigen with two non-Hodgkin lympho patients, one of whom had previously developed an anti-globulin response to the parental antibody (Riechmann, L. et al., Nature 332:323-327 (1988); Hale, G. et al., Lanc 5 i:1394-1399 (1988)). A murine antibody to the interleukin 2 receptor has also recently be humanized (Queen, C. et al., Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989)) as I potential immunosuppressive reagent. Additional references related to humanization antibodies include Co etal., Proc. Natl. Acad. Sci. USA 88:2869-2873 (1991 ); Gorman eta Proc. Natl. Acad. Sci. USA 88:4181-4185 (1991 ); Daugherty et al., Nucleic Acids Resear 10 19(9):2471 -2476 (1991 ); Brown et al., Proc. Natl. Acad. Sci. USA 88:2663-2667 (1991 Junghans et al., Cancer Research 50:1495-1502 (1990). In some cases, substituting CDRs from rodent antibodies for the human CDRs in hum frameworks is sufficient to transfer high antigen binding affinity (Jones, P. T. et al., Natu 321 :522-525 (1986); Verhoeyen, M. etal., Science 239:1 534-1536 (1988)), whereas in oth 15 cases it has been necessary to additionally replace one (Riechmann, L. et al., Natu 332:323-327 (1988)) or several (Queen, C. et al., Proc. Natl. Acad. Sci. U 86:10029-10033 (1989)) framework region (FR) residues. See also Co et al., supra. For a given antibody a small number of FR residues are anticipated to be important f antigen binding. Firstly for example, certain antibodies have been shown to contain a few ' 20 residues which directly contact antigen in crystal structures of antibody-antigen complex (e.g., reviewed in Davies, D. R. et al., Ann. Rev. Biochem. 59:439-473 (1990)). Secondl a number of FR residues have been proposed by Chothia, Lesk and colleagues (Chothia, C. Lesk, A. M., J. Mol. Biol. 196:901-917 (1987); Chothia, C. et al., Nature 342:877-8 (1989); Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)) as critically affecting t 25 conformation of particular CDRs and thus their contribution to antigen binding. See al Margolies et al., Proc. Natl. Acad. Sci. USA 72:2180-2184 (1975). It is also known that, in a few instances, an antibody variable domain (either V H or may contain glycosylation sites, and that this glycosylation may improve or abolish antig binding, Pluckthun, Biotechnology 9:545-51 (1991 ); Spiegelberg etal., Biochemistry 9:421 30 4223 (1970); Wallic ef al., J. Exp. Med. 168:1099-1 109 (1988); Sox etal., Proc. Natl. Aca Sci. USA 66:975-982 (1970); Margni et al., Ann. Rev. Immunol. 6:535-554 (1988 Ordinarily, however, glycosylation has no influence on the antigen-binding properties of antibody, Pluckthun, supra, (1991 ). The three-dimensional structure of immunoglobulin chains has been studied, and cryst structures for intact immunoglobulins, for a variety of immunoglobulin fragments, and f antibody-antigen complexes have been published (see e.g., Saul et al., Journal of Biologic Chemistry 25:585-97 (1978); Sherif f et al. , Proc. Natl. Acad. Sci. USA 84:8075-79 (1987 Segal et al., Proc. Natl. Acad. Sci. USA 71 :4298-4302 (1974); Epp et al., Biochemist 14(22):4943-4952 (1975); Marquart et al.. J. Mol. Biol. 141 :369-391 (1980); Furey et a J. Mol. Biol. 167:661-692 (1983); Snow and Amzel, Protein: Structure, Function, a Genetics 1 :267-279, Alan R. Liss, Inc. pubs. (1986); Chothia and Lesk, J. Mol. Biol. 196:90 917 (1987); Chothia etal., Nature 342:877-883 (1989); Chothia et al., Science 233:755-5 (1986); Huber et al., Nature 264:415-420 (1976); Bruccoleri et al., Nature 335:564-56 (1988) and Nature 336:266 (1988); Sherman etal., Journal of Biological Chemistry 263:406 4074 (1988); Amzel and Poljak, Ann. Rev. Biochem. 48:961-67 (1979); Silverton etal., Pro Natl. Acad. Sci. USA 74:5140-5144 (1977); and Gregory et al., Molecular Immunolog 24:821-829 (1987). It is known that the function of an antibody is dependent on its thre dimensional structure, and that amino acid substitutions can change the three-dimension structure of an antibody. Snow and Amzel, supra. It has previously been shown that th antigen binding affinity of a humanized antibody can be increased by mutagenesis based upo molecular modelling (Riechmann, L. etal., Nature 332:323-327 (1988); Queen, C. etal., Pro Natl. Acad. Sci. USA 86:10029-10033 (1989)). Humanizing an antibody with retention of high affinity for antigen and other desire biological activities is at present difficult to achieve using currently available procedures Methods are needed for rationalizing the selection of sites for substitution in preparing suc antibodies and thereby increasing the efficiency of antibody humanization. The proto-oncogene HER2 (human epidermal growth factor receptor 2) encodes protein tyrosine kinase (p185 HER2 ) that is related to and somewhat homologous to the huma epidermal growth factor receptor (see Coussens, L. et al., Science 230:1 132-1 139 (1985) Yamamoto, T. et al., Nature 319:230-234 (1986); King, C. R. et al., Science 229:974-97 (1985)). HER2 is also known in the field as c-erbB-2, and sometimes by the name of the ra homolog, neu. Amplification and/or overexpression of HER2 is associated with multiple huma malignancies and appears to be integrally involved in progression of 25-30% of human breas and ovarian cancers (Slamon, D. J. et al., Science 235:177-182 (1987), Slamon, D. J. etal., Science 244:707-712 (1989)). Furthermore, the extent of amplification is inversely correlated with the observed median patient survival time (Slamon, supra. Science 1989). The murine monoclonal antibody known as muMAb4D5 (Fendly, B. M. et al., Cance Res. 50:1550-1558 (1990)), directed against the extracellular domain (ECD) of p185 HER2 , specifically inhibits the growth of tumor cell lines overexpressing p185 HER2 in monolay culture or in soft agar (Hudziak, R. M. et al., Molec. Cell. Biol. 9:1 165-1 172 (1989); Lupu, et al., Science 249:1552-1555 (1990)). MuMAb4D5 also has the potential of enhancin tumor cell sensitivity to tumor necrosis factor, an important effector molecule i macrophage-mediated tumor cell cytotoxicity (Hudziak, supra, 1989; Shepard, H. M. an Lewis, G. D. J. Clinical Immunology 8:333-395 (1988)). Thus muMAb4D5 has potential f clinical intervention in and imaging of carcinomas in which p185 HER2 is overexpressed. Th muMAb4D5 and its uses are described in PCT application WO 89/06692 published 27 Jul 1989. This murine antibody was deposited with the ATCC and designated ATCC CRL 1046 However, this antibody may be immunogenic in humans. It is therefore an object of this invention to provide methods for the preparation antibodies which are less antigenic in humans than non-human antibodies but have desire antigen binding and other characteristics and activities. It is a further object of this invention to provide methods for the efficient humanizatio of antibodies, i.e. selecting non-human amino acid residues for importation into a huma antibody background sequence in such a fashion as to retain or improve the affinity of the no human donor antibody for a given antigen. It is another object of this invention to provide humanized antibodies capable of bindin pl 85 HER2 Other objects, features, and characteristics of the present invention will becom apparent upon consideration of the following description and the appended claims. Summary of the Invention The objects of this invention are accomplished by a method for making a humanize antibody comprising amino acid sequence of an import, non-human antibody and a huma antibody, comprising the steps of: a. obtaining the amino acid sequences of at least a portion of an import antibod variable domain and of a consensus variable domain; b. identifying Complementarity Determining Region (CDR) amino acid sequence in the import and the human variable domain sequences; c. substituting an import CDR amino acid sequence for the corresponding huma CDR amino acid sequence; d. aligning the amino acid sequences of a Framework Region (FR) of the impor antibody and the corresponding FR of the consensus antibody; e. identifying import antibody FR residues in the aligned FR sequences that ar non-homologous to the corresponding consensus antibody residues; f. determining if the non-homologous import amino acid residue is reasonabl expected to have at least one of the following effects: 1. non-covalently binds antigen directly, 2. interacts with a CDR; or 3. participates in the V L - V H interface; and g. for any non-homologous import antibody amino acid residue which is reasonabl expected to have at least one of these effects, substituting that residue for th corresponding amino acid residue in the consensus antibody FR sequence. Optionally, the method of this invention comprises the additional steps of determinin if any non-homologous residues identified in step (e) are exposed on the surface of the domai or buried within it, and if the residue is exposed but has none of the effects identified in ste (f), retaining the consensus residue. Additionally, in certain embodiments the method of this invention comprises the featur wherein the corresponding consensus antibody residues identified in step (e) above ar selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H, 92H, 93H, an 103H (utilizing the numbering system set forth in Kabat, E. A. et al., Sequences of Protein of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987)). In certain embodiments, the method of this invention comprises the additional steps o searching either or both of the import, non-human and the consensus variable domain sequences for glycosylation sites, determining if the glycosylation is reasonably expected to be important for the desired antigen binding and biological activity of the antibody (i.e., determining if the glycosylation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosylation enhances or weakens antigen binding, or is important for maintaining antibody affinity). If the import sequence bears the glycosylation site, it is preferred to substitute that site for the corresponding residues in the consensus human if the glycosylation site is reasonably expected to be important. If only the consensus sequence, and not the import, bears the glycosylation site, it is preferred to eliminate that glycosylation site or substitute therefor the corresponding amino acid residues from the import sequence. Another embodiment of this invention comprises aligning import antibody and t consensus antibody FR sequences, identifying import antibody FR residues which are no homologous with the aligned consensus FR sequence, and for each such non-homologo import antibody FR residue, determining if the corresponding consensus antibody resid represents a residue which is highly conserved across all species at that site, and if it is conserved, preparing a humanized antibody which comprises the consensus antibody ami acid residue at that site. Certain alternate embodiments of the methods of this invention comprise obtaining t amino acid sequence of at least a portion of an import, non-human antibody variable doma having a CDR and a FR, obtaining the amino acid sequence of at least a portion of a consens antibody variable domain having a CDR and a FR, substituting the non-human CDR for t human CDR in the consensus antibody variable domain, and then substituting an amino ac residue for the consensus amino acid residue at at least one of the following sites: a. (in the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85 87L, 98L, or b. (in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76 78H, 91 H, 92H, 93H, and 103H. In preferred embodiments, the non-CDR residue substituted at the consensus FR site is th residue found at the corresponding location of the non-human antibody. Optionally, this just-recited embodiment comprises the additional steps of following th method steps appearing at the beginning of this summary and determining whether a particul amino acid residue can reasonably be expected to have undesirable effects. This invention also relates to a humanized antibody comprising the CDR sequence an import, non-human antibody and the FR sequence of a human antibody, wherein an amin acid residue within the human FR sequence located at any one of the sites 4L, 35L, 36L, 38 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74 75H, 76H, 78H, 91 H, 92H, 93H, and 103H has been substituted by another residue. I preferred embodiments, the residue substituted at the human FR site is the residue found the corresponding location of the non-human antibody from which the non-human CDR wa obtained. In other embodiments, no human FR residue other than those set forth in this grou has been substituted. This invention also encompasses specific humanized antibody variable domains, a isolated polypeptides having homology with the following sequences. 1. SEQ. ID NO. 1 , which is the light chain variable domain of a humanized version muMAb4D5: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLESG SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRT 2. SEQ. ID NO. 2, which is the heavy chain variable domain of a humanized version muMAb4D5): EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTL TVSS In another aspect, this invention provides a consensus antibody variable domain amin acid sequence for use in the preparation of humanized antibodies, methods for obtainin using, and storing a computer representation of such a consensus sequence, and compute comprising the sequence data of such a sequence. In one embodiment, the followin consensus antibody variable domain amino acid sequences are provided: SEQ. ID NO. 3 (light chain): DIQMTQSPSSLSASVGDRVTITCRASQDVSSYLAWYQQKPGKAPKLLIYAASSLESGV SRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSLPYTFGQGTKVEIKRT, and SEQ. ID NO. 4 (heavy chain): EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVAVISENGGY RYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGT VTVSS Brief Description of the Drawings FIGURE 1A shows the comparison of the V L domain amino acid residues o muMAb4D5, huMAb4D5, and a consensus sequence (Fig. 1A, SEQ.ID NO. 5, SEQ. ID NO. 1 and SEQ. ID NO. 3, respectively). FIGURE 1 B shows the comparison between the V H domai amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig. 1 B, SE ID NO. 6, SEQ. ID NO. 2 and SEQ. ID NO. 4, respectively). Both Figs 1 A and 1 B use t generally accepted numbering scheme from Kabat, E. A., et al., Sequences of Proteins Immunological Interest (National Institutes of Health, Bethesda, MD (1987)). In both Fig. 1 and Fig. 1 B, the CDR residues determined according to a standard sequence definition (as i Kabat, E. A. et al., Sequences of Proteins of Immunological Interest (National Institutes Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath the sequences, a the CDR residues determined according to a structural definition (as in Chothia, C. & Lesk, M., J. Mol. Biol. 196:901 -917 (1987)) are indicated by the second, lower underlines. Th mismatches between genes are shown by the vertical lines. FIGURE 2 shows a scheme for humanization of muMAb4D5 V L and V H by gen conversion mutagenesis. FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants. Relativ cell proliferation was determined as described (Hudziak, R. M. et al., Molec. Cell. Bio 9:1 165-1 172 (1989)) and data (average of triplicate determinations) are presented as percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) an huMAb4D5-1 (I). FIGURE 4 shows a stereo view of σ-carbon tracing for a model of huMAb4D5-8 V L an V H . The CDR residues (Kabat, E. A. et al., Sequences of Proteins of Immunological Intere (National Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of V residues A71 , T73, A78, S93, Y102 and V L residues Y55 plus R66 (see Table 3) are shown FIGURE 5 shows an amino acid sequence comparison of V L (top panel) and V H (low panel) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., Exp. Med. 175, 217-225 (1992) with a humanized variant of this antibody (huxCD3v9). Als shown are consensus sequences (most commonly occurring residue or pair of residues) of th most abundant human subgroups, namely V L K 1 and V H III upon which the humanize sequences are based (Kabat, E. A. etal., Sequences of Proteins of Immunological Interest, 5 edition. National Institutes of Health, Bethesda, MD, USA (1991 )). The light chain sequences muxCD3, huxCD3v9 and hu/d-correspond to SEQ.ID.NOs 16, 17, and 18, respectively. Th heavy chain sequences--muxCD3, huxCD3v9 and hu/fl-correspond to SEQ.ID.NOs 19, 20, an 21 , respectively. Residues which differ between muxCD3 and huxCD3v9 are identified by a asterisk (*), whereas those which differ between humanized and consensus sequences ar identified by a sharp sign (#). A bullet (°) denotes that a residue at this position has bee found to contact antigen in one or more crystallographic structures of antibody/antige complexes (Kabat et al., 1991 ; Mian, I. S. et al., J. Mol. Biol. 217, 133-151 (1991 )). Th location of CDR residues according to a sequence definition (Kabat et al., 1991) and structural definition (Chothia and Lesk, supra 1987) are shown by a line and carats ( Λ ) beneat the sequences, respectively. FIGURE 6A compares murine and humanized amino acid sequences for the heavy chai of an anti-CD 18 antibody. H52H4-160 (SEQ. ID. NO. 22) is the murine sequence, and pH5 8.0 (SEQ. ID. NO. 23) is the humanized heavy chain sequence. pH52-8.0 residue 143S is th final amino acid in the variable heavy chain domain V H , and residue 144A is the first amin acid in the constant heavy chain domain C H - | . FIGURE 6B compares murine and humanized amino acid sequences for the light chai of an antϊ-CD18 antibody. H52L6-158 (SEQ. ID. NO. 24) is the murine sequence, and pH52 9.0 (SEQ. ID. NO. 25) is the humanized light chain sequence. pH52-9.0 residue 128T is th final amino acid in the light chain variable domain V L , and residue 129V is the first amino aci in the light chain constant domain C L - Detailed Description of the Invention Definitions In general, the following words or phrases have the indicated definitions when used i the description, examples, and claims: The murine monoclonal antibody known as muMAb4D5 (Fendly, B. M. et al., Cance Res. 50:1550-1558 (1990)) is directed against the extracellular domain (ECD) of p185 HER2 . The muMAb4D5 and its uses are described in PCT application WO 89/06692 published 27 July 1989. This murine antibody was deposited with the ATCC and designated ATCC CRL 10463. In this description and claims, the terms muMAb4D5, chMAb4D5 and huMAb4D5 represent murine, chimerized and humanized versions of the monoclonal antibody 4D5, respectively. A humanized antibody for the purposes herein is an immunoglobulin amino acid sequence variant or fragment thereof which is capable of binding to a predetermined antigen and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are referred to herein as "import" residues, which are typically taken from an "import" antibody domain. particularly a variable domain. An import residue, sequence, or antibody has a desired affini and/or specificity, or other desirable antibody biological activity as discussed herein. In general, the humanized antibody will comprise substantially all of at least one, a typically two, variable domains (Fab, Fab', F(ab') 2 , Fabc, Fv) in which all or substantially of the CDR regions correspond to those of a non-human immunoglobulin and all or substantial all of the FR regions are those of a human immunoglobulin consensus sequence. T humanized antibody optimally also will comprise at least a portion of an immunoglobuli constant region (Fc), typically that of a human immunoglobulin. Ordinarily, the antibody w contain both the light chain as well as at least the variable domain of a heavy chain. Th antibody also may include the CH1 , hinge, CH2, CH3, and CH4 regions of the heavy chain The humanized antibody will be selected from any class of immunoglobulins, includin IgM, IgG, IgD, IgA and IgE, and any isotype, including IgG 1 , lgG2, lgG3 and lgG4. Usually t constant domain is a complement fixing constant domain where it is desired that th humanized antibody exhibit cytotoxic activity, and the class is typically IgG,. Where suc cytotoxic activity is not desirable, the constant domain may be of the lgG 2 class. Th humanized antibody may comprise sequences from more than one class or isotype, an selecting particular constant domains to optimize desired effector functions is within th ordinary skill in the art. The FR and CDR regions of the humanized antibody need not correspond precisely t the parental sequences, e.g., the import CDR or the consensus FR may be mutagenized b substitution, insertion or deletion of at least one residue so that the CDR or FR residue at th site does not correspond to either the consensus or the import antibody. Such mutation however, will not be extensive. Usually, at least 75% of the humanized antibody residues wi correspond to those of the parental FR and CDR sequences, more often 90%, and mo preferably greater than 95%. In general, humanized antibodies prepared by the method of this invention are produce by a process of analysis of the parental sequences and various conceptual humanized product using three dimensional models of the parental and humanized sequences. Three dimension immunoglobulin models are commonly available and are familiar to those skilled in the ar Computer programs are available which illustrate and display probable three dimension conformational structures of selected candidate immunoglobulin sequences. Inspection these displays permits analysis of the likely role of the residues in the functioning of th candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability the candidate immunoglobulin to bind its antigen. Residues that influence antigen binding are defined to be residues that are substantial responsible for the antigen affinity or antigen specificity of a candidate immunoglobulin, in positive or a negative sense. The invention is directed to the selection and combination of residues from the consensus and import sequence so that the desired immunoglobul characteristic is achieved. Such desired characteristics include increases in affinity and great specificity for the target antigen, although it is conceivable that in some circumstances t opposite effects might be desired, in general, the CDR residues are directly and mo substantially involved in influencing antigen binding (although not all CDR residues are involved and therefore need not be substituted into the consensus sequence). However, F residues also have a significant effect and can exert their influence in at least three way They may noncovalently directly bind to antigen, they may interact with CDR residues and the may affect the interface between the heavy and light chains. A residue that noncovalently directly binds to antigen is one that, by three dimension analysis, is reasonably expected to noncovalently directly bind to antigen. Typically, it i necessary to impute the position of antigen from the spatial location of neighboring CDRs an the dimensions and structure of the target antigen. In general, only those humanized antibod residues that are capable of forming salt bridges, hydrogen bonds, or hydrophobic interaction are likely to be involved in non-covalent antigen binding, however residues which have atom which are separated from antigen spatially by 3.2 Angstroms or less may also non-covalentl interact with antigen. Such residues typically are the relatively larger amino acids having th side chains with the greatest bulk, such as tyrosine, arginine, and lysine. Antigen-binding F residues also typically will have side chains that are oriented into an envelope surrounding th solvent oriented face of a CDR which extends about 7 Angstroms into the solvent from th CDR domain and about 7 Angstroms on either side of the CDR domain, again as visualized b three dimensional modeling. A residue that interacts with a CDR generally is a residue that either affects th conformation of the CDR polypeptide backbone or forms a noncovalent bond with a CD residue side chain. Conformation-affecting residues ordinarily are those that change the spatia position of any CDR backbone atom (N, Cσ, C, 0, Cβ) by more than about 0.2 Angstroms. Backbone atoms of CDR sequences are displaced for example by residues that interrupt o modify organized structures such as beta sheets, helices or loops. Residues that can exert profound affect on the conformation of neighboring sequences include proline and glycine, bot of which are capable of introducing bends into the backbone. Other residues that can displac backbone atoms are those that are capable of participating in salt bridges and hydrogen bonds. A residue that interacts with a CDR side chain is one that is reasonably expected t form a noncovalent bond with a CDR side chain, generally either a salt bridge or hydroge bond. Such residues are identified by three dimensional positioning of their side chains. A sa or ion bridge could be expected to form between two side chains positioned within about 2.5 3.2 Angstroms of one another that bear opposite charges, for example a lysinyl and glutamyl pairing. A hydrogen bond could be expected to form between the side chains residue pairs such as seryl or threonyl with aspartyl or glutamyl (or other hydrogen acceptin residues). Such pairings are well known in the protein chemistry art and will be apparent t the artisan upon three dimensional modeling of the candidate immunoglobulin. Immunoglobulin residues that affect the interface between heavy and light chai variable regions ("the V L - V H interface") are those that affect the proximity or orientation the two chains with respect to one another. Certain residues involved in interchain interaction are already known and include V L residues 34, 36, 38, 44, 46, 87, 89, 91 , 96, and 98 an V H residues 35, 37, 39, 45, 47, 91 , 93, 95, 100, and 103 (utilizing the nomenclature set fort in Kabat etal., Sequences of Proteins of Immunological Interest (National Institutes of Healt Bethesda, MD, 1987)). Additional residues are newly identified by the inventors herein, an include 43L, 85L, 43H and 60H. While these residues are indicated for IgG only, they ar applicable across species. In the practice of this invention, import antibody residues that ar reasonably expected to be involved in interchain interactions are selected for substitution int the consensus sequence. It is believed that heretofore no humanized antibody has bee prepared with an intrachain-affecting residue selected from an import antibody sequence. Since it is not entirely possible to predict in advance what the exact impact of a give substitution will be it may be necessary to make the substitution and assay the candidat antibody for the desired characteristic. These steps, however, are per se routine and we within the ordinary skill of the art. CDR and FR residues are determined according to a standard sequence definition (Kaba etal., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesd MD (1987), and a structural definition (as in Chothia and Lesk, J. Mol. Biol. 196:901 -91 (1987). Where these two methods result in slightly different identifications of a CDR, th structural definition is preferred, but the residues identified by the sequence definition metho are considered important FR residues for determination of which framework residues to impor into a consensus sequence. Throughout this description, reference is made to the numbering scheme from Kaba E. A., et al., Sequences of Proteins of Immunological Interest (National Institutes of Healt Bethesda, MD (1987) and (1991 ). In these compendiums, Kabat lists many amino aci sequences for antibodies for each subclass, and lists the most commonly occurring amino aci for each residue position in that subclass. Kabat uses a method for assigning a residue numb to each amino acid in a listed sequence, and this method for assigning residue numbers ha become standard in the field. The Kabat numbering scheme is followed in this descriptio For purposes of this invention, to assign residue numbers to a candidate antibody amin acid sequence which is not included in the Kabat compendium, one follows the followin steps. Generally, the candidate sequence is aligned with any immunoglobulin sequence or an consensus sequence in Kabat. Alignment may be done by hand, or by computer usin commonly accepted computer programs; an example of such a program is the Align 2 progra discussed in this description. Alignment may be facilitated by using some amino acid residue which are common to most Fab sequences. For example, the light and heavy chains eac typically have two cysteines which have the same residue numbers; in V-_ domain the tw cysteines are typically at residue numbers 23 and 88, and in the V H domain the two cystein residues are typically numbered 22 and 92. Framework residues generally, but not always have approximately the same number of residues, however the CDRs will vary in size. Fo example, in the case of a CDR from a candidate sequence which is longer than the CDR in th sequence in Kabat to which it is aligned, typically suffixes are added to the residue number t indicate the insertion of additional residues (see, e.g. residues lOOabcde in Fig. 5). Fo candidate sequences which, for example, align with a Kabat sequence for residues 34 and 3 but have no residue between them to align with residue 35, the number 35 is simply no assigned to a residue. Thus, in humanization of an import variable sequence, where one cuts out an entire human or consensus CDR and replaces it with an import CDR sequence, (a) the exact number of residues may be swapped, leaving the numbering the same, (b) fewer import amino acid residues may be introduced than are cut, in which case there will be a gap in the residue numbers, or (c) a larger number of amino acid residues may be introduced then were cut, in which case the numbering will involve the use of suffixes such as 10Oabcde. The terms "consensus sequence" and "consensus antibody" as used herein refers to an amino acid sequence which comprises the most frequently occurring amino acid residues at each location in all immunoglobulins of any particular subclass or subunϊt structure. The consensus sequence may be based on immunoglobulins of a particular species or of many species. A "consensus" sequence, structure, or antibody is understood to encompass a consensus human sequence as described in certain embodiments of this invention, and to refer to an amino acid sequence which comprises the most frequently occurring amino acid residu at each location in all human immunoglobulins of any particular subclass or subunit structur This invention provides consensus human structures and consensus structures which consid other species in addition to human. The subunit structures of the five immunoglobulin classes in humans are as follow Class Heavy Chain Suhπla.s.sfi. Light Chain Mni p r-niar Formula ( _* 2 ) - ( _) (σ_>. 2 ) n a , (σ^ 2 ) n a (μ_*_) 5 ■ 0 ) 5 (δ 2 Xϊ) , (<J_ 1 2 ) (e 2 κ 2 ) , 2 ) In preferred embodiments of an lgGj/1 human consensus sequence, the consens variable domain sequences are derived from the most abundant subclasses in the sequen compilation of Kabat et al., Sequences of Proteins of Immunological Interest, National Institut of Health, Bethesda MD (1987), namely V L K subgroup I and V H group III. In such preferr embodiments, the V L consensus domain has the amino acid sequenc DIQMTQSPSSLSASVGDRVTITCRASQDVSSYLAWYQQKPGKAPKLLIYAASSLESGVPSRFS SGSGTDFTLTISSLQPEDFATYYCQQYNSLPYTFGQGTKVEIKRT (SEQ. ID NO. 3); t h e V H c o n s e n s u s d o m a i n h a s t h e a m i n o a c i d s e q u e n c e EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLEWVAVISENGGYTRYA SVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS (SE ID NO. 4). These sequences include consensus CDRs as well as consensus FR residues (see for examp in Fig. 1 ). While not wishing to be limited to any particular theories, it may be that these preferr embodiments are less likely to be immunogenic in an individual than less abundant subclasse However, in other embodiments, the consensus sequence is derived from other subclasses human immunoglobulin variable domains. In yet other embodiments, the consensus sequen is derived from human constant domains. Identity or homology with respect to a specified amino acid sequence of this inventi is defined herein as the percentage of amino acid residues in a candidate sequence that a identical with the specified residues, after aligning the sequences and introducing gaps, necessary, to achieve the maximum percent homology, and not considering any conservati substitutions as part of the sequence identity. None of N-terminal, C-terminal or intern extensions, deletions, or insertions into the specified sequence shall be construed as affecti homology. All sequence alignments called for in this invention are such maximal homolo alignments. While such alignments may be done by hand using conventional methods, suitable computer program is the "Align 2" program for which protection is being sought fro the U.S. Register of Copyrights (Align 2, by Genentech, Inc., application filed 9 Decemb 1991 ). "Non-homologous" import antibody residues are those residues which are not identic to the amino acid residue at the analogous or corresponding location in a consensus sequenc after the import and consensus sequences are aligned. The term "computer representation" refers to information which is in a form that ca be manipulated by a computer. The act of storing a computer representation refers to the a of placing the information in a form suitable for manipulation by a computer. This invention is also directed to novel polypeptides, and in certain aspects, isolate novel humanized anti-p185 HER2 antibodies are provided. These novel anti-p185 HER antibodies are sometimes collectively referred to herein as huMAb4D5, and also sometime as the light or heavy chain variable domains of huMAb4D5, and are defined herein to be an polypeptide sequence which possesses a biological property of a polypeptide comprising th following polypeptide sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLESGV SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRT (SEQ. ID NO. 1 which is the light chain variable domain of huMAb4D5); or EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLV TVSS (SEQ. ID NO. 2, which is the heavy chain variable domain of huMAb4D5). "Biological property", as relates for example to anti-p185 R2 , for the purposes herei means an in vivo effector or antigen-binding function or activity that is directly or indirectl performed by huMAb4D5 (whether in its native or denatured conformation). Effector function include p185 HER2 binding, any hormonal or hormonal antagonist activity, any mitogenic o agonist or antagonist activity, any cytotoxic activity. An antigenic function means possessio of an epitope or antigenic site that is capable of cross-reacting with antibodies raised again the polypeptide sequence of huMAb4D5. Biologically active huMAb4D5 is defined herein as a polypeptide that shares an effect function of huMAb4D5. A principal known effector function of huMAb4D5 is its ability to bi to p185 HER2 . Thus, the biologically active and antigenically active huMAb4D5 polypeptides that a the subject of certain embodiments of this invention include the sequence of the enti translated nucleotide sequence of huMAb4D5; mature huMAb4D5; fragments thereof havi a consecutive sequence of at least 5, 10, 1 5, 20, 25, 30 or 40 amino acid residues comprisi sequences from muMAb4D5 plus residues from the human FR of huMAb4D5; amino ac sequence variants of huMAb4D5 wherein an amino acid residue has been inserted N- or terminal to, or within, huMAb4D5 or its fragment as defined above; amino acid sequen variants of huMAb4D5 or its fragment as defined above wherein an amino acid residue huMAb4D5 or its fragment as defined above has been substituted by another residue, includi predetermined mutations by, e.g., site-directed or PCR mutagenesis; derivatives of huMAb4D or its fragments as defined above wherein huMAb4D5 or its fragments have been covale modified, by substitution, chemical, enzymatic, or other appropriate means, with a moie other than a naturally occurring amino acid; and glycosylation variants of huMAb4D5 (inserti of a glycosylation site or deletion of any glycosylation site by deletion, insertion or substituti of suitable residues). Such fragments and variants exclude any polypeptide heretofo identified, including muMAb4D5 or any known polypeptide fragment, which are anticipato order 35 U.S.C.102 as well as polypeptides obvious thereover under 35 U.S.C. 103. An "isolated" polypeptide means polypeptide which has been identified and separat and/or recovered from a component of its natural environment. Contaminant components its natural environment are materials which would interfere with diagnostic or therapeutic us for the polypeptide, and may include enzymes, hormones, and other proteinaceous nonproteinaceous solutes. In preferred embodiments, for example, a polypeptide produ comprising huMAb4D5 will be purified from a cell culture or other synthetic environment ( to greater than 95% by weight of protein as determined by the Lowry method, and mo preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residu of N-terminal or internal amino acid sequence by use of a gas- or liquid-phase sequenator (su as a commercially available Applied Biosystems sequenator Model 470, 477, or 473), or ( to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie bl or, preferably, silver stain. Isolated huMAb4D5 includes huMAb4D5 in situ within recombina cells since at least one component of the huMAb4D5 natural environment will not be present Ordinarily, however, isolated huMAb4D5 will be prepared by at least one purification step. In accordance with this invention, huMAb4D5 nucleic acid is RNA or DNA containin greater than ten bases that encodes a biologically or antigenically active huMAb4D5, i complementary to nucleic acid sequence encoding such huMAb4D5, or hybridizes to nuclei acid sequence encoding such huMAb4D5 and remains stably bound to it under stringent conditions, and comprises nucleic acid from a muMAb4D5 CDR and a human FR region. Preferably, the huMAb4D5 nucleic acid encodes a polypeptide sharing at least 75% sequence identity, more preferably at least 80%, still more preferably at least 85%, even more preferably at 90%, and most preferably 95%, with the huMAb4D5 amino acid sequence. Preferably, a nucleic acid molecule that hybridizes to the huMAb4D5 nucleic acid contains at least 20, more preferably 40, and most preferably 90 bases. Such hybridizing or complementary nucleic acid, however, is further defined as being novel under 35 U.S.C. 102 and unobvious under 35 U.S.C. 103 over any prior art nucleic acid. Stringent conditions are those that (1 ) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCI/0.0015 M sodium citrate/0/1 % NaDodS0 4 at 50° C; (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1 % bovine serum albumin/0/1 % Ficoll/0/1 % polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42° C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 g/ml), 0.1 % SDS, and 10% dextran sulfate at 42 C, with washes at 42 C in 0.2 x SSC and 0.1 % SDS. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood sequences. Eukaryotic cells are known to utilize promoters, polyadenylatϊon signals, and enhancers. Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the ca of a secretory leader, contiguous and in reading phase. However enhancers do not have be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sit do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord wi conventional practice. An "exogenous" element is defined herein to mean nucleic acid sequence that is foreig to the cell, or homologous to the cell but in a position within the host cell nucleic acid in whi the element is ordinarily not found. As used herein, the expressions "cell," "cell line," and "cell culture" are use interchangeably and all such designations include progeny. Thus, the words "transformant and "transformed cells" include the primary subject cell and cultures derived therefrom witho regard for the number of transfers. It is also understood that all progeny may not be precisel identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny th have the same function or biological activity as screened for in the originally transformed c are included. Where distinct designations are intended, it will be clear from the context. "Oligonucleotides" are short-length, single- or double-stranded polydeoxynucleotide that are chemically synthesized by known methods (such as phosphotriester, phosphite, phosphoramidite chemistry, using solid phase techniques such as described in EP 266,03 published 4 May 1988, or via deoxynucleoside H-phosphonate intermediates as described b Froehler et al., Nucl. Acids Res.. 14: 5399-5407 [1986]). They are then purified o polyacrylamide gels. The technique of "polymerase chain reaction," or "PCR," as used herein generally refer to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DN are amplified as described in U.S. Pat. No. 4,683,195 issued 28 July 1987. Generall sequence information from the ends of the region of interest or beyond needs to be availabl such that oligonucleotide primers can be designed; these primers will be identical or similar i sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides o the two primers may coincide with the ends of the amplified material. PCR can be used t amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDN transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generall Mullis et al., Cold Sprin g Harbor Svmo. Quant. Biol., 51 : 263 (1987); Erlich, ed., PC Technology. (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, b not the only, example of a nucleic acid polymerase reaction method for amplifying a nuclei acid test sample, comprising the use of a known nucleic acid (DNA or RNA) as a primer an utilizes a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid or amplify or generate a specific piece of nucleic acid which is complementary to a particul nucleic acid. Suitable Methods for Practicing the Invention Some aspects of this invention include obtaining an import, non-human antibod variable domain, producing a desired humanized antibody sequence and for humanizing a antibody gene sequence are described below. A particularly preferred method of changing gene sequence, such as gene conversion from a non-human or consensus sequence into humanized nucleic acid sequence, is the cassette mutagenesis procedure described in Exampl 1. Additionally, methods are given for obtaining and producing antibodies generally, whic apply equally to native non-human antibodies as well as to humanized antibodies. Generally, the antibodies and antibody variable domains of this invention ar conventionally prepared in recombinant cell culture, as described in more detail below Recombinant synthesis is preferred for reasons of safety and economy, but it is known t prepare peptides by chemical synthesis and to purify them from natural sources; suc preparations are included within the definition of antibodies herein. Molecular Modeling An integral step in our approach to antibody humanization is construction of compute graphics models of the import and humanized antibodies. These models are used to determin if the six complementarity-determining regions (CDRs) can be successfully transplanted fro the import framework to a human one and to determine which framework residues from th import antibody, if any, need to be incorporated into the humanized antibody in order t maintain CDR conformation, in addition, analysis of the sequences of the import and humanized antibodies and reference to the models can help to discern which framewor residues are unusual and thereby might be involved in antigen binding or maintenance of proper antibody structure. AH of the humanized antibody models of this invention are based on a single three- dimensional computer graphics structure hereafter referred to as the consensus structure. This consensus structure is a key distinction from the approach of previous workers in the field, who typically begin by selecting a human antibody structure which has an amino acid sequence which is similar to the sequence of their import antibody. The consensus structure of one embodiment of this invention was built in five steps described below. Step 1 : Seven Fab X-ray crystal structures from the Brookhaven Protein Da Bank were used (entries 2FB4, 2RHE, 3FAB, and 1 REI which are human structures, and 2MC 1 FBJ, and 2HFL which are murine structures). For each structure, protein mainchain geomet and hydrogen bonding patterns were used to assign each residue to one of three seconda structure types: alpha-helix, beta-strand or other (i.e. non-helix and non-strand). T immunoglobulin residues used in superpositioning and those included in the consens structure are shown in Table 1 . Table I Immunoglobulin Residues Used in Superpositioning and Those Included in the Consensus Structure l g ε RMS C 0.40 0.60 0.53 0.54 0.48 0.50 VH domain Ig £ 2FB4 2MCP 3FAB 1FBJ 2HFL Consensus b 3-8 18-25 18-25 18-25 18-25 18-25 17-23 34-39 34-39 34-39 34-39 34-39 33-41 46-52 46-52 46-52 46-52 46-52 45-51 57-61 59-63 56-60 57-61 57-61 57-61 68-71 70-73 67-70 68-71 68-71 66-71 78-84 80-86 77-83 78-84 78-84 75-82 92-99 94-101 91-98 92-99 92-99 88-94 102-108 RMS C 0.43 0.85 0.62 0.91 RMS d 0.91 0.73 0.77 0.92 a Four-letter code for Protein Data Bank file. b Residue numbers for th crystal structures are taken from the Protein Data Bank files. Residue numbers for the consensus structure are according to Kabat et al. c Root-mean-square deviation in Λ for (N.Cα.C) atoms superimposed on 2FB4. d Root-mean-square deviation in A for (N.Cα.C) atoms superimposed on 2HFL. Step 2: Having identified the alpha-helices and beta-strands in each of the sev structures, the structures were superimposed on one another using the INSIGHT comput program (Biosym Technologies, San Diego, CA) as follows: The 2FB4 structure was arbitrari chosen as the template (or reference) structure. The 2FB4 was held fixed in space and t other six structures rotated and translated in space so that their common secondary structur elements (i.e. alpha-helices and beta-strands) were oriented such that these common elemen were as close in position to one another as possible. (This superpositioning was perform using accepted mathematical formulae rather than actually physically moving the structur by hand.) Step 3: With the seven structures thus superimposed, for each residue in t template (2FB4) Fab one calculates the distance from the template alpha-carbon atom (Cσ) the analogous C atom in each of the other six superimposed structures. This results in a tab of Cσ-Cσ distances for each residue position in the sequence. Such a table is necessary i order to determine which residue positions will be included in the consensus model. Generall if all Cσ-Cσ distances for a given residue position were ≤ 1.θA, that position was included i the consensus structure. If for a given position only one Fab crystal structure was > 1 .θ the position was included but the outlying crystal structure was not included in the next ste (for this position only). In general, the seven ^-strands were included in the consens structure while some of the loops connecting the ^-strands, e.g. complementarity-determinin regions (CDRs), were not included in view of Cσ divergence. Step 4: For each residue which was included in the consensus structure after ste 3, the average of the coordinates for individual mainchain N, Cσ, C, 0 and Cβ atoms wer calculated. Due to the averaging procedure, as well as variation in bond length, bond angl and dihedral angle among the crystal structures, this "average" structure contained some bon lengths and angles which deviated from standard geometry. For purposes of this inventio "standard geometry" is understood to include geometries commonly accepted as typical, suc as the compilation of bond lengths and angles from small molecule structures in Weiner, S. et. al., J. Amer. Chem. Soc, 106: 765-784 (1984). Step 5: In order to correct these deviations, the final step was to subject th "average" structure to 50 cycles of energy minimization (DISCOVER program, Biosy Technologies) using the AMBER (Weiner, S.J. et. a/., J. Amer. Chem. Soc, 106: 765-78 (1984)) parameter set with only the Cσ coordinates fixed (i.e. all other atoms are allowed t move) (energy minimization is described below). This allowed any deviant bond lengths an angles to assume a standard (chemically acceptable) geometry. See Table II. 2 Table II Average Bond Lengths and Angles for "Average" (Before) and Energy-Minimized Consensus (After 50 Cycles) Structures Values in parentheses are standard deviations. Note that while some bond length and angle averages did not change appreciably after energy-minimization, the corresponding standard deviations are reduced due to deviant geometries assuming standard values after energy-minimization. Standard geometry values are from the AMBER forcefield as implemented in DISCOVER (Biosym Technologies). The consensus structure might conceivably be dependent upon which crystal structu was chosen as the template on which the others were superimposed. As a test, the enti procedure was repeated using the crystal structure with the worst superposition versus 2FB i.e. the 2HFL Fab structure, as the new template (reference). The two consensus structur compare favorably (root-mean-squared deviation of 0.1 1 A for all N, Cσ and C atoms). Note that the consensus structure only includes mainchain (N, Cσ, C, 0, Cβ atom coordinates for only those residues which are part of a conformation common to all seven ray crystal structures. For the Fab structures, these include the common ^-strands (whic comprise two ^-sheets) and a few non-CDR loops which connect these ?-strands. T consensus structure does not include CDRs or sidechains, both of which vary in the conformation among the seven structures. Also, note that the consensus structure include only the VL and VH domains. This consensus structure is used as the archetype. It is not particular to any specie and has only the basic shape without side chains. Starting with this consensus structure th model of any import, human, or humanized Fab can be constructed as follows. Using th amino acid sequence of the particular antibody VL and VH domains of interest, a comput graphics program (such as INSIGHT, Biosym Technologies) is used to add sidechains and CD to the consensus structure. When a sidechain is added, its conformation is chosen on th basis of known Fab crystal structures (see the Background section for publications of suc crystal structures) and rotamer libraries (Ponder, J.W. & Richards, F. M., J. Mol. Biol. 19 775-791 (1987)). The model also is constructed so that the atoms of the sidechain ar positioned so as to not collide with other atoms in the Fab. CDRs are added to the model (now having the backbone plus side chains) as follow The size (i.e. number of amino acids) of each import CDR is compared to canonical CD structures tabulated by Chothia et al., Nature, 342:877-883 (1989)) and which were derive from Fab crystals. Each CDR sequence is also reviewed for the presence or absence of certai specific amino acid residues which are identified by Chothia as structurally important: e.g. lig chain residues 29 (CDR1 ) and 95 (CDR3), and heavy chain residues 26, 27, 29 (CDR1 ) an 55 (CDR2). For light chain CDR2, and heavy chain CDR3, only the size of the CDR i compared to the Chothia canonical structure. If the size and sequence (i.e. inclusion of th specific, structurally important residues as denoted by Chothia etal.) of the import CDR agree in size and has the same structurally important residues as those of a canonical CDR, then th mainchain conformation of the import CDR in the model is taken to be the same as that of th canonical CDR. This means that the import sequence is assigned the structural configuratio of the canonical CDR, which is then incorporated in the evolving model. However, if no matching canonical CDR can be assigned for the import CDR, then o of two options can be exercised. First, using a program such as INSIGHT (Biosy Technologies), the Brookhaven Protein Data Bank can be searched for loops with a similar si to that of the import CDR and these loops can be evaluated as possible conformations for t import CDR in the model. Minimally, such loops must exhibit a conformation in which no loo atom overlaps with other protein atoms. Second, one can use available programs whic calculate possible loop conformations, assuming a given loop size, using methods such a described by Bruccoleri et al.. Nature 335: 564-568 (1988). When all CDRs and sidechains have been added to the consensus structure to give th final model (import, human or humanized), the model is preferably subjected to energ minimization using programs which are available commercially (e.g. DISCOVER, Biosy Technologies). This technique uses complex mathematical formulae to refine the model b performing such tasks as checking that all atoms are within appropriate distances from on another and checking that bond lengths and angles are within chemically acceptable limits. Models of a humanized, import or human antibody sequence are used in the practic of this invention to understand the impact of selected amino acid residues of the activity o the sequence being modeled. For example, such a model can show residues which may b important in antigen binding, or for maintaining the conformation of the antibody, as discusse in more detail below. Modeling can also be used to explore the potential impact of changin any amino acid residue in the antibody sequence. Methods for Obtaining a Humanized Antibody Seouence In the practice of this invention, the first step in humanizing an import antibody i deriving a consensus amino acid sequence into which to incorporate the import sequences Next a model is generated for these sequences using the methods described above. In certai embodiments of this invention, the consensus human sequences are derived from the mos abundant subclasses in the sequence compilation of Kabat et al. (Kabat, E. A. et al. Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD 1987)), namely V L K subgroup I and V H group III, and have the sequences indicated in th definitions above. While these steps may be taken in different order, typically a structure for the candidate humanized antibody is created by transferring the at least one CDR from the non-human, import sequence into the consensus human structure, after the entire corresponding human CDR has been removed. The humanized antibody may contain human replacements of t non-human import residues at positions within CDRs as defined by sequence variability (Kab E. A. et al., Sequences of Proteins of Immunological Interest (National Institutes of Healt Bethesda, MD, 1987)) or as defined by structural variability (Chothia, C. & Lesk, A. M., J. M Biol. 196:901 -917 (1987)). For example, huMAb4D5 contains human replacements of t muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kab E. A. et al., Sequences of Proteins of Immunological Interest (National Institutes of Healt Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C. & Lesk, A. J. Mol. Biol. 196:901 -917 (1987)): V L -CDR1 K24R, V L -CDR2 R54L and V L -CDR2 T56S. Differences between the non-human import and the human consensus framewo residues are individually investigated to determine their possible influence on CDR conformati and/or binding to antigen. Investigation of such possible influences is desirably perform through modeling, by examination of the characteristics of the amino acids at particul locations, or determined experimentally through evaluating the effects of substitution mutagenesis of particular amino acids. In certain preferred embodiments of this invention, a humanized antibody is ma comprising amino acid sequence of an import, non-human antibody and a human antibod utilizing the steps of: a. obtaining the amino acid sequences of at least a portion of an import antibo variable domain and of a consensus human variable domain; b. identifying Complementarity Determining Region (CDR) amino acid sequenc in the import and the human variable domain sequences; c. substituting an import CDR amino acid sequence for the corresponding huma CDR amino acid sequence; d. aligning the amino acid sequences of a Framework Region (FR) of the impo antibody and the corresponding FR of the consensus antibody; e. identifying import antibody FR residues in the aligned FR sequences that a non-homologous to the corresponding consensus antibody residues; f. determining if the non-homologous import amino acid residue is reasonabl expected to have at least one of the following effects: 1 . non-covalently binds antigen directly, 2. interacts with a CDR; or 3. participates in the V L - V H interface; and g. for any non-homologous import antibody amino acid residue which is reasonabl expected to have at least one of these effects, substituting that residue for t corresponding amino acid residue in the consensus antibody FR sequence. Optionally, one determines if any non-homologous residues identified in step (e) a exposed on the surface of the domain or buried within it, and if the residue is exposed but h none of the effects identified in step (f), one may retain the consensus residue. Additionally, in certain embodiments the corresponding consensus antibody residu identified in step (e) above are selected from the group consisting of 4L, 35L, 36L, 38L, 43 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75 76H, 78H, 91 H, 92H, 93H, and 103H (utilizing the numbering system set forth in Kabat, A. et al., Sequences of Proteins of Immunological Interest (National Institutes of Healt Bethesda, MD, 1987)). In preferred embodiments, the method of this invention comprises the additional ste of searching either or both of the import, non-human and the consensus variable domai sequences for glycosylation sites, determining if the glycosylation is reasonably expected t be important for the desired antigen binding and biological activity of the antibody (i.e determining if the glycosylation site binds to antigen or changes a side chain of an amino aci residue that binds to antigen, or if the glycosylation enhances or weakens antigen binding, is important for maintaining antibody affinity). If the import sequence bears the glycosylatio site, it is preferred to substitute that site for the corresponding residues in the consensu human sequence if the glycosylation site is reasonably expected to be important. If only th consensus sequence, and not the import, bears the glycosylation site, it is preferred t eliminate that glycosylation site or substitute therefor the corresponding amino acid residue from the import sequence. Another preferred embodiment of the methods of this invention comprises alignin import antibody and the consensus antibody FR sequences, identifying import antibody F residues which are non-homologous with the aligned consensus FR sequence, and for eac such non-homologous import antibody FR residue, determining if the corresponding consensu antibody residue represents a residue which is highly conserved across all species at that site and if it is so conserved, preparing a humanized antibody which comprises the consensu antibody amino acid residue at that site. In certain alternate embodiments, one need not utilize the modeling and evaluation step described above, and may instead proceed with the steps of obtaining the amino acid sequenc of at least a portion of an import, non-human antibody variable domain having a CDR and a FR obtaining the amino acid sequence of at least a portion of a consensus human antibo var= _>le domain having a CDR and a FR, substituting the non-human CDR for the human CD in the consensus human antibody variable domain, and then substituting an amino acid resid for the consensus amino acid residue at at least one of the following sites: a. (in the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85 87L, 98L, or b. (in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76 78H, 91 H, 92H, 93H, and 103H. Preferably, the non-CDR residue substituted at the consensus FR site is the residue found the corresponding location of the non-human antibody. If desired, one may utilize the oth method steps described above for determining whether a particular amino acid residue ca reasonably be expected to have undesirable effects, and remedying those effects. If after making a humanized antibody according to the steps above and testing it activity one is not satisfied with the humanized antibody, one preferably reexamines th potential effects of the amino acids at the specific locations recited above. Additionally, it i desirable to reinvestigate any buried residues which are reasonably expected to affect the V L V H interface but may not directly affect CDR conformation. It is also desirable to reevaluat the humanized antibody utilizing the steps of the methods claimed herein. In certain embodiments of this invention, amino acid residues in the consensus huma sequence are substituted for by other amino acid residues. In preferred embodiments, residue from a particular ' non-human import sequence are substituted, however there ar circumstances where it is desired to evaluate the effects of other amino acids. For exampl if after making a humanized antibody according to the steps above and testing its activity on is not satisfied with the humanized antibody, one may compare the sequences of other classe or subgroups of human antibodies, or classes or subgroups of antibodies from the particul non-human species, and determine which other amino acid side chains and amino acid residue are found at particular locations and substituting such other residues. Antibodies Certain aspects of this invention are directed to natural antibodies and to monoclon antibodies, as illustrated in the Examples below and by antibody hybridomas deposited wit the ATCC (as described below). Thus, the references throughout this description to the us of monoclonal antibodies are intended to include the use of natural or native antibodies as we as humanized and chimeric antibodies. As used herein, the term "antibody" includes th antibody variable domain and other separable antibody domains unless specifically exclude In accordance with certain aspects of this invention, antibodies to be humanized (impo antibodies) are isolated from continuous hybrid cell lines formed by the fusion o antigen-primed immune lymphocytes with myeloma cells. In certain embodiments, the antibodies of this invention are obtained by routin screening. Polγclonal antibodies to an antigen generally are raised in animals by multipl subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may b useful to conjugate the antigen or a fragment containing the target amino acid sequence to protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional o derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation throug cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succini anhydride, SOCI 2 , or R'N = C = NR, where R and R 1 are different alkyl groups. The route and schedule of the host animal or cultured antibody-producing cell therefrom are generally in keeping with established and conventional techniques for antibod stimulation and production. While mice are frequently employed as the test model, it i contemplated that any mammalian subject including human subjects or antibody-producing cells obtained therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lines. Animals are typically immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 μg of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1 /5 to 1/10 the original amount of conjugate in Freund's complete adjuvant (or other suitable adjuvant) by subcutaneous injection at multiple sites. 7 to 14 days later animals are bled and the serum is assayed for antigen titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, monoclonal antibodies are prepared by recovering immune lymphoid cells— typically spleen cells or lymphocytes from lymph node tissue—from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by Epstein-Bar r (EB)-virus transformation and screening for clones expressing the desired antibod The hybridoma technique described originally by Kohler and Milstein, Eur. J. Immunol. 6:51 (1976) has been widely applied to produce hybrid cell lines that secrete high levels monoclonal antibodies against many specific antigens. It is possible to fuse cells of one species with another. However, it is preferable th the source of the immunized antibody producing cells and the myeloma be from the sam species. The hybrid cell lines can be maintained in culture in vitro in cell culture media. The ce lines of this invention can be selected and/or maintained in a composition comprising th continuous cell line in hypoxanthine-aminopterin thymidine (HAT) medium, in fact, once th hybridoma cell line is established, it can be maintained on a variety of nutritionally adequat media. Moreover, the hybrid cell lines can be stored and preserved in any number conventional ways, including freezing and storage under liquid nitrogen. Frozen cell lines ca be revived and cultured indefinitely with resumed synthesis and secretion of monoclon antibody. The secreted antibody is recovered from tissue culture supernatant by convention methods such as precipitation. Ion exchange chromatography, affinity chromatography, or th like. The antibodies described herein are also recovered from hybridoma cell cultures b conventional methods for purification of IgG or IgM as the case may be that heretofore hav been used to purify these immunoglobulins from pooled plasma, e.g. ethanol or polyethylen glycol precipitation procedures. The purified antibodies are sterile filtered, and optionally ar conjugated to a detectable marker such as an enzyme or spin label for use in diagnostic assay of the antigen in test samples. While routinely rodent monoclonal antibodies are used as the source of the impor antibody, the invention is not limited to any species. Additionally, techniques developed f the production of chimeric antibodies (Morrison etal., Proc. Natl. Acad. Sci., 81 :6851 (1984) Neuberger et al., Nature 312:604 (1984); Takeda etal., Nature 314:452 (1985)) by splicin the genes from a mouse antibody molecule of appropriate antigen specificity together wit genes from a human antibody molecule of appropriate biological activity (such as ability t activate human complement and mediate ADCC) can be used; such antibodies are within th scope of this invention. Techniques for creating recombinant DNA versions of the antigen-binding regions o antibody molecules (known as Fab fragments) which bypass the generation of monoclona antibodies are encompassed within the practice of this invention. One extracts antibody specific messenger RNA molecules from immune system cells taken from an immunized animal transcribes these into complementary DNA (cDNA), and clones the cDNA into a bacteria expressions system. One example of such a technique suitable for the practice of thi invention was developed by researchers at Scripps/Str atagene, and incorporates a proprietar bacteriophage lambda vector system which contains a leader sequence that causes th expressed Fab protein to migrate to the periplasmic space (between the bacterial cel membrane and the cell wall) or to be secreted. One can rapidly generate and screen grea numbers of functional FAb fragments for those which bind the antigen. Such FAb fragments with specificity for the antigen are specifically encompassed within the term "antibody" as i is defined, discussed, and claimed herein. Amino Acid Seouence Variants Amino acid sequence variants of the antibodies and polypeptides of this invention (referred to in herein as the target polypeptide) are prepared by introducing appropriate nucleotide changes into the DNA encoding the target polypeptide, or by in vitro synthesis of the desired target polypeptide. Such variants include, for example, humanized variants of non- human antibodies, as well as deletions from, or insertions or substitutions of, residues within particular amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the target polypeptide, such as changing the number or position of glycosylation sites, altering any membrane anchoring characteristics, and/or altering the intra-cellular location of the target polypeptide by inserting, deleting, or otherwise affecting any leader sequence of the native target polypeptide. In designing amino acid sequence variants of target polypeptides, the location of the mutation site and the nature of the mutation will depend on the target polypeptide characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1 ) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3. In certain embodiments, these choices are guided by the methods for creating humanized sequences set forth above. A useful method for identification of certain residues or regions of the target polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (Science. 244: 1081-1085 [1989]). Here, a residue or group of target residues are identified (e.g., charged residues such as ar asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (mo preferably alanine or polyalanine) to affect the interaction of the amino acids with th surrounding aqueous environment in or outside the cell. Those domains demonstratin functional sensitivity to the substitutions then are refined by introducing further or oth variants at or for the sites of substitution. Thus, while the site for introducing an amino aci sequence variation is predetermined, the nature of the mutation per se need not b predetermined. For example, to optimize the performance of a mutation at a given site, al scanning or random mutagenesis may be conducted at the target codon or region and th expressed target polypeptide variants are screened for the optimal combination of desire activity. There are two principal variables in the construction of amino acid sequence variant the location of the mutation site and the nature of the mutation. In general, the location an nature of the mutation chosen will depend upon the target polypeptide characteristic to b modified. Amino acid sequence deletions of antibodies are generally not preferred, as maintainin the generally configuration of an antibody is believed to be necessary for its activity. An deletions will be selected so as to preserve the structure of the target antibody. Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions rangin in length from one residue to polypeptides containing a hundred or more residues, as well a intrasequence insertions of single or multiple amino acid residues. Intrasequence insertion (i.e., insertions within the target polypeptide sequence) may range generally from about 1 t 10 residues, more preferably 1 to 5, most preferably 1 to 3. Examples of terminal insertion include the target polypeptide with an N-terminal methionyl residue, an artifact of the direc expression of target polypeptide in bacterial recombinant cell culture, and fusion of heterologous N-terminal signal sequence to the N-terminus of the target polypeptide molecul to facilitate the secretion of the mature target polypeptide from recombinant host cells. Suc signal sequences generally will be obtained from, and thus homologous to, the intended hos cell species. Suitable sequences include STII or Ipp for E. coli, alpha factor for yeast, and vir signals such as herpes gD for mammalian cells. Other insertional variants of the target polypeptide include the fusion to the N- or C terminus of the target polypeptide of immunogenic polypeptides, e.g., bacterial polypeptide such as beta-lactamase or an enzyme encoded by the E. coli trp locus, or yeast protein, an C-terminal fusions with proteins having a long half-life such as immunoglobulin constan regions (or other immunoglobulin regions), albumin, or ferritϊn, as described in WO 89/0292 published 6 April 1989. Another group of variants are amino acid substitution variants. These variants have least one amino acid residue in the target polypeptide molecule removed and a different residu inserted in its place. The sites of greatest interest for substitutional mutagenesis include site identified as the active site(s) of the target polypeptide, and sites where the amino acids foun in the target polypeptide from various species are substantially different in terms of side-chai bulk, charge, and/or hydrophobicity. Other sites for substitution are described infr considering the effect of the substitution of the antigen binding, affinity and othe characteristics of a particular target antibody. Other sites of interest are those in which particular residues of the target polypeptide obtained from various species are identical. These positions may be important for th biological activity of the target polypeptide. These sites, especially those falling within sequence of at least three other identically conserved sites, are substituted in a relativel conservative manner. If such substitutions result in a change in biological activity, then othe changes are introduced and the products screened until the desired effect is obtained. Substantial modifications in function or immunological identity of the target polypeptid are accomplished by selecting substitutions that differ significantly in their effect o maintaining (a) the structure of the polypeptide backbone in the area of the substitution, fo example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecul at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties: (1 ) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gin, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another. Such substituted residues may be introduced into regions of the target polypeptide that are homologous with other antibodies of the same class or subclass, or, more preferably, into the non-homologous regions of the molecule. Any cysteine residues not involved in maintaining the proper conformation of target polypeptide also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. DNA encoding amino acid sequence variants of the target polypeptide is prepared b a variety of methods known in the art. These methods include, but are not limited to, isolatio from a natural source (in the case of naturally occurring amino acid sequence variants) preparation by oligonucieotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, an cassette mutagenesis of an earlier prepared variant or a non-variant version of the targ polypeptide. A particularly preferred method of gene conversion mutagenesis is describe below in Example 1 . These techniques may utilized target polypeptide nucleic acid (DNA RNA), or nucleic acid complementary to the target polypeptide nucleic acid. Oligonucieotide-mediated mutagenesis is a preferred method for preparing substitutio deletion, and insertion variants of target polypeptide DNA. This technique is well known in th art as described bv Adelman et al.. DNA. 2: 183 (1983). Briefly, the target polypeptide DN is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA templat where the template is the single-stranded form of a plasmid or bacteriophage containing th unaltered or native DNA sequence of the target polypeptide. After hybridization, a DN polymerase is used to synthesize an entire second complementary strand of the template tha will thus incorporate the oligonucleotide primer, and will code for the selected alteration in th target polypeptide DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optim oligonucleotide will have 12 to 15 nucleotides that are completely complementary to th template on either side of the nucleotide(s) coding for the mutation. This ensures that th oligonucleotide will hybridize properly to the single-stranded DNA template molecule. Th oligonucleotides are readily synthesized using techniques known in the art such as tha described by Crea et al. (Proc. Natl. Acad. Sci. USA. 75: 5765 [1978]). Single-stranded DNA template may also be generated by denaturing double-strande plasmid (or other) DNA using standard techniques. For alteration of the native DNA sequence (to generate amino acid sequence variants for example), the oligonucleotide is hybridized to the single-stranded template under suitabl hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DN polymerase I, is then added to synthesize the complementary strand of the template using th oligonucleotide as a primer for synthesis. A heterodupiex molecule is thus formed such tha one strand of DNA encodes the mutated form of the target polypeptide, and the other stran (the original template) encodes the native, unaltered sequence of the target polypeptide. Thi heterodupiex molecule is then transformed into a suitable host cell, usually a prokaryote suc as £. coli JM101. After the cells are grown, they are plated onto agarose plates and screen using the oligonucleotide primer radiolabeled with 32-phosphate to identify the bacteri colonies that contain the mutated DNA. The mutated region is then removed and placed in a appropriate vector for protein production, generally an expression vector of the type typicall employed for transformation of an appropriate host. The method described immediately above may be modified such that a homoduple molecule is created wherein both strands of the plasmid contain the mutation(s). Th modifications are as follows: The single-stranded oligonucleotide is annealed to th single-stranded template as described above. A mixture of three deoxyribonucieotides deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), i combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained fro Amersham Corporation). This mixture is added to the tempiate-oligonucleotide complex Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the templat except for the mutated bases is generated. In addition, this new strand of DNA will contai dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion After the template strand of the double-stranded heterodupiex is nicked with a appropriate restriction enzyme, the template strand can be digested with E_xo.HI nuclease o another appropriate nuclease past the region that contains the site(s) to be mutagenized. Th reaction is then stopped to leave a molecule that is only partially single-stranded. A complet double-stranded DNA homoduplex is then formed using DNA polymerase in the presence o all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecul can then be transformed into a suitable host cell such as E. coli JM101 , as described above. DNA encoding target polypeptide variants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed. In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce th desired mutant. The first round is as described for the single mutants: wild-type DNA is use for the template, an oligonucleotide encoding the first desired amino acid substitution(s) i annealed to this template, and the heterodupiex DNA molecule is then generated. The secon round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis a the template. Thus, this template already contains one or more mutations. Th oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed t this template, and the resulting strand of DNA now encodes mutations from both the first an second rounds of mutagenesis. This resultant DNA can be used as a template in a third roun of mutagenesis, and so on. PCR mutagenesis is also suitable for making amino acid variants of target polypeptide While the following discussion refers to DNA, it is understood that the technique also find application with RNA. The PCR technique generally refers to the following procedure (se Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA ar used as starting material in a PCR, primers that differ slightly in sequence from th corresponding region in a template DNA can be used to generate relatively large quantities o a specific DNA fragment that differs from the template sequence only at the positions wher the primers differ from the template. For introduction of a mutation into a plasmid DNA, on of the primers is designed to overlap the position of* the mutation and to contain the mutation the sequence of the other primer must be identical to a stretch of sequence of the opposit strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. I is preferred, however, that the sequence of the second primer is located within 20 nucleotides from that of the first, such that in the end the entire amplified region of DN bounded by the primers can be easily sequenced. PCR amplification using a primer pair lik the one just described results in a population of DNA fragments that differ at the position o the mutation specified by the primer, and possibly at other positions, as template copying i somewhat error-prone. If the ratio of template to product material is extremely low, the vast majority o product DNA fragments incorporate the desired mutation(s). This product material is used t replace the corresponding region in the plasmid that served as PCR template using standar DNA technology. Mutations at separate positions can be introduced simultaneously by eithe using a mutant second primer, or performing a second PCR with different mutant primers an ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (o more)-part ligation. In a specific example of PCR mutagenesis, template plasmid DNA (1 μg) is lineari by digestion with a restriction endonuciease that has a unique recognition site in the plas DNA outside of the region to be amplified. Of this material, 100 ng is added to a PCR mixt containing PCR buffer, which contains the four deoxynucleotide tri-phosphates and is includ in the GeneAmp ® kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, C and 25 pmole of each oligonucleotide primer, to a final volume of 50 μl. The reaction mixt is overlayed with 35 μl mineral oil. The reaction is denatured for 5 minutes at 100°C, plac briefly on ice, and then 1 μ\ Thermυs aquaticus (Taq) DNA polymerase (5 units/ /l, purchas from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA) is added below the mineral oil lay The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Elm Cetus) programmed as follows: 2 min. at 55°C, then 30 sec. at 72«-C, then 19 cycles of t following: 30 sec. at 94°C, 30 sec. at 55°C, and 30 sec. at 72°C. At the end of the program, the reaction vial is removed from the thermal cycler and t aqueous phase transferred to a new vial, extracted with phenol/chloroform (50:50:vol), a ethanol precipitated, and the DNA is recovered by standard procedures. This material subsequently subjected to the appropriate treatments for insertion into a vector. Another method for preparing variants, cassette mutagenesis, is based on the techniq described by Wells etal. (Gene, 34: 315 [1985]). The starting material is the plasmid (or oth vector) comprising the target polypeptide DNA to be mutated. The codon.s) in the targ polypeptide DNA to be mutated are identified. There must be a unique restricti endonuciease site on each side of the identified mutation site(s). If no such restriction sit exist, they may be generated using the above-described oligonucieotide-mediated mutagenes method to introduce them at appropriate locations in the target polypeptide DNA. After t restriction sites have been introduced into the plasmid, the plasmid is cut at these sites t linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between t restriction sites but containing the desired mutation(s) is synthesized using standar procedures. The two strands are synthesized separately and then hybridized together usin standard techniques. This double-stranded oligonucleotide is referred to as the cassette. Thi cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearize plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains th mutated target polypeptide DNA sequence. Insertion of DNA into a Cloning Vehicle The cDNA or genomic DNA encoding the target polypeptide is inserted into a replicabl vector for further cloning (amplification of the DNA) or for expression. Many vectors ar available, and selection of the appropriate vector will depend on 1 ) whether it is to be used fo DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector and 3) the host cell to be transformed with the vector. Each vector contains variou components depending on its function (amplification of DNA or expression of DNA) and th host cell for which it is compatible. The vector components generally include, but are no limited to, one or more of the following: a signal sequence, an origin of replication, one or mor marker genes, an enhancer element, a promoter, and a transcription termination sequence. (a) Signal Seguence Component In general, the signal sequence may be a component of the vector, or it may be a par of the target polypeptide DNA that is inserted into the vector. The target polypeptides of this invention may be expressed not only directly, but als as a fusion with a heterologous polypeptide, preferably a signal sequence or other polypeptid having a specific cleavage site at the N-terminus of the mature protein or polypeptide. I general, the signal sequence may be a component of the vector, or it may be a part of th target polypeptide DNA that is inserted into the vector. Included within the scope of thi invention are target polypeptides with any native signal sequence deleted and replaced wit a heterologous signal sequence. The heterologous signal sequence selected should be one tha is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. Fo prokaryotic host cells that do not recognize and process the native target polypeptide signa sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, fo example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stabl enterotoxin II leaders. For yeast secretion the native target polypeptide signal sequence ma be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders. In mammalia cell expression the native signal sequence is satisfactory, although other mammalian signa sequences may be suitable. (b) Origin of Replication Component Both expression and cloning vectors contain a nucleic acid sequence that enables th vector to replicate in one or more selected host cells. Generally, in cloning vectors thi sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Suc sequences are well known for a variety of bacteria, yeast, and viruses. The origin replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus. VS or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replicatio component is not needed for mammalian expression vectors (the SV40 origin may typically b used only because it contains the early promoter). Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in a least one class of organisms but can be transfected into another organism for expression. Fo example, a vector is cloned in E. coli and then the same vector is transfected into yeast o mammalian cells for expression even though it is not capable of replicating independently o the host cell chromosome. DNA may also be amplified by insertion into the host genome. This is readil accomplished using Bacillus species as hosts, for example, by including in the vector a DN sequence that is complementary to a sequence found in Bacillus genomic DNA. Transfectio of Bacillus with this vector results in homologous recombination with the genome and insertio of the target polypeptide DNA. However, the recovery of genomic DNA encoding the targe polypeptide is more complex than that of an exogenously replicated vector because restrictio enzyme digestion is required to excise the target polypeptide DNA. (c) Selection Gene Component Expression and cloning vectors should contain a selection gene, also termed a selectabl marker. This gene encodes a protein necessary for the survival or growth of transformed hos cells grown in a selective culture medium. Host cells not transformed with the vecto containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate, ortetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli. One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet.. 1: 327 [1982]), mycophenolic acid (Mulligan etal.. Science, 209: 1422 [1980]) or hygromycin (Sugden etal Mol. Cell. Biol.. .5: 410-413 [19851). The three examples given above employ bacterial gene under eukaryotic control to convey resistance to the appropriate drug G418 or neomyci (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively. Another example of suitable selectable markers for mammalian cells are those th enable the identification of cells competent to take up the target polypeptide nucleic acid, suc as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell transformants ar placed under selection pressure which only the transformants are uniquely adapted to surviv by virtue of having taken up the marker. Selection pressure is imposed by culturing th transformants under conditions in which the concentration of selection agent in the mediu is successively changed, thereby leading to amplification of both the selection gene and th DNA that encodes the target polypeptide. Amplification is the process by which genes i greater demand for the production of a protein critical for growth are reiterated in tande within the chromosomes of successive generations of recombinant cells. Increased quantitie of the target polypeptide are synthesized from the amplified DNA. For example, cells transformed with the DHFR selection gene are first identified b culturing all of the transformants in a culture medium that contains methotrexate (Mtx), competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employe is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared an propagated as described by Urlaub and Chasin, Proc. Natl. Acad. Sci. USA. 77: 4216 [1980] The transformed cells are then exposed to increased levels of methotrexate. This leads to th synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of othe DNA comprising the expression vectors, such as the DNA encoding the target polypeptide This amplification technique can be used with any otherwise suitable host, e.g., ATCC No CCL61 CHO-K1 , notwithstanding the presence of endogenous DHFR if, for example, a mutan DHFR gene that is highly resistant to Mtx is employed (EP 1 17,060). Alternatively, host cell (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transforme with DNA sequences encoding the target polypeptide, wild-type DHFR protein, and anothe selectable marker such as aminoglγcoside 3' phosphotransferase (APH) can be selected by cel growth in medium containing a selection agent for the selectable marker such as a aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Pat. No 4,965,199. A suitable selection gene for use in yeast is the trpΛ gene present in the yeast plasmi YRp7 (Stinchcomb et al.. Nature. 282: 39 [1979]; Kingsman et al.. Gene. 7: 141 [1979]; o Tschemper et al., Gene, 10: 1 57 [1980]). The trpλ gene provides a selection marker for mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 4407 or PEP4-1 (Jones, Genetics, 85: 12 [1977]). The presence of the trrjl lesion in the yeast ho cell genome then provides an effective environment for detecting transformation by growt in the absence of tryptophan. Similarly, Z.et/2-deficient yeast strains (ATCC 20,622 or 38,62 are complemented by known plasmids bearing the Leu2 gene. (d) Promoter Component Expression and cloning vectors usually contain a promoter that is recognized by the hos organism and is operably linked to the target polypeptide nucleic acid. Promoters ar untranslated sequences located upstream (5') to the start codon of a structural gene (generall within about 100 to 1000 bp) that control the transcription and translation of a particula nucleic acid sequence, such as that encoding the target polypeptide, to which they ar operably linked. Such promoters typically fall into two classes, inducible and constitutive Inducible promoters are promoters that initiate increased levels of transcription from DN under their control in response to some change in culture conditions, e.g. the presence o absence of a nutrient or a change in temperature. At this time a large number of promoter recognized by a variety of potential host cells are well known. These promoters are operabl linked to DNA encoding the target polypeptide by removing the promoter from the source DN by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native target polypeptide promoter sequence and many heterologous promoters ma be used to direct amplification and/or expression of the target polypeptide DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target polypeptide as compared to the native target polypeptide promoter. Promoters suitable for use with prokaryotic hosts include the yff-lactamase and lactose promoter systems (Chang etal., Nature. 275: 615 [1978]; and Goeddel et al.. Nature, 281 : 544 [19791), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res.. 8_: 4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA. 80: 21-25 [1983]). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding the target polypeptide (Siebenlist et al., Cell, 20: 269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also generally will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the target polypeptide. Suitable promoting sequences for use with yeast hosts include the promoters for phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem.. 255: 2073 [1980]) or oth glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg.. T 149 [1968]; and Hollan Biochemistry. 17: 4900119781). such asenolase, glvceraldehvde-3-phosDhate dehvdrooenas hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomeras 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucos isomerase, and glucokinase. Other yeast promoters, which are inducible promoters having the additional advantag of transcription controlled by growth conditions, are the promoter regions for alcoh dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated wit nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, an enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters f use in yeast expression are further described in Hitzeman etal., EP 73,657A. Yeast enhancer also are advantageously used with yeast promoters. Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have a AT-rich region located approximately 25 to 30 bases upstream from the site wher transcription is initiated. Another sequence found 70 to 80 bases upstream from the start o transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3 end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition o the poly A tail to the 3' end of the coding sequence. All of these sequences are suitabl inserted into mammalian expression vectors. Target polypeptide transcription from vectors in mammalian host cells is controlled b promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (U 2,21 1 ,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferabl Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter o an immunoglobulin promoter, from heat-shock promoters, and from the promoter normall associated with the target polypeptide sequence, provided such promoters are compatible wit the host cell systems. The early and late promoters of the SV40 virus are conveniently obtained as an SV4 restriction fragment that also contains the SV40 viral origin of replication. Fiers etal.. Nature 273:1 13 (1978): Mulligan and Berg, Science, 209: 1422-1427 (1980); Pavlakis et al., Proc Natl. Acad. Sci. USA. 78: 7398-7402 (1981 ). The immediate early promoter of the huma cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment. Greenaway etal. Gene, 18: 355-360 (1982). A system for expressing DNA in mammalian hosts using th bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A modification of thi system is described in U.S. 4,601 ,978. See also Gray et al., Nature. 295: 503-508 (198 on expressing cDNA encoding immune interferon in monkey cells; , Reyes etal.. Nature, 29 598-601 (1982) on expression of human ^-interferon cDNA in mouse cells under the contr of a thymidine kinase promoter from herpes simplex virus, Canaani and Berα, Proc. Natl. Aca Sci. USA. 79: 5166-5170 (1982) on expression of the human interferon βl gene in culture mouse and rabbit cells, and Gorman etal.. Proc. Natl. Acad. Sci. USA. 79: 6777-6781 (1982 on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embry fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rou sarcoma virus long terminal repeat as a promoter. (e) Enhancer Element Component Transcription of DNA encoding the target polypeptide of this invention by highe eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter t increase its transcription. Enhancers are relatively orientation and position independent having been found 5' (Laimins etal., Proc. Natl. Acad. Sci. USA. 78: 993 [1981]) and 3' (Lusky e al., Mol. Cell Bio., 3.: 1 108 [1983]) to the transcription unit, within an intron (Banerji et al., Cell, 33: 729 [1983]) as well as within the coding sequence itself (Osborne et al., Mol. Cell Bio., 4: 1293 [1984]). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, σ-fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature, 297: 17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the target polypeptide DNA, but is preferably located at a site 5' from the promoter. (f) Transcription Termination Component Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal. human, or nucleated cells from other multicellular organisms) will also contain sequence necessary for the termination of transcription and for stabilizing the mRNA. Such sequence are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic o viral DNAs or cDNAs. These regions contain nucleotide segments transcribed a polyadenylated fragments in the untranslated portion of the mRNA encoding the targe polypeptide. The 3' untranslated regions also include transcription termination sites. Construction of suitable vectors containing one or more of the above listed component the desired coding and control sequences employs standard ligation techniques. Isolate plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generat the plasmids required. For analysis to confirm correct sequences in plasmids constructed, the ligation mixture are used to transform E. coli K12 strain 294 (ATCC 31 ,446) and successful transformant selected by ampicillin or tetracycline resistance where appropriate. Plasmids from th transformants are prepared, analyzed by restriction endonuciease digestion, and/or sequence by the method of Messing et al., Nucleic Acids Res.. 9.: 309 (1981 ) or by the method o Maxam et a/., Methods in Enzvmoloαv. 65: 499 (1980). Particularly useful in the practice of this invention are expression vectors that provid for the transient expression in mammalian cells of DNA encoding the target polypeptide. I general, transient expression involves the use of an expression vector that is able to replicat efficiently in a host cell, such that the host cell accumulates many copies of the expressio vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expressio vector. Transient expression systems, comprising a suitable expression vector and a host cell allow for the convenient positive identification of polypeptides encoded by cloned DNAs, a well as for the rapid screening of such polypeptides for desired biological or physiologica properties. Thus, transient expression systems are particularly useful in the invention fo purposes of identifying analogs and variants of the target polypeptide that have targe polγpeptide-like activity. Other methods, vectors, and host cells suitable for adaptation to the synthesis of th target polypeptide in recombinant vertebrate cell culture are described in Gething etal.. Nature 293: 620-625 [1981 ]; Mantei etal.. Nature. 281 : 40-46 [1979]; Levinson era/.; EP 1 17,060; and EP 1 17,058. A particularly useful plasmid for mammalian cell culture expression of th target polypeptide is pRK5 (EP pub. no. 307,247) or pSVI6B. Selection and Transformation of Host Cells Suitable host cells for cloning or expressing the vectors herein are the prokaryot yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, suc as Gram-negative or Gram-positive organisms, for example, E coli, Bacilli such as B. subtili Pseudomonas species such as P. aeruginosa. Salmonella typhimurium, or Serratia marcescan One preferred E. coli cloning host is E. coli 294 (ATCC 31 ,446), although other strains suc as E. coli B, E. coliχΛ 71G (ATCC 31 ,537), and E. coli W31 10 (ATCC 27,325) are suitable These examples are illustrative rather than limiting. Preferably the host cell should secret minimal amounts of proteolytic enzymes. Alternatively, in vitro methods of cloning, e.g. PC or other nucleic acid polymerase reactions, are suitable. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast ar suitable hosts for target polypeptide-encoding vectors. Saccharomyces cerevisiae , or commo baker's yeast, is the most commonly used among lower eukaryotic host microorganisms However, a number of other genera, species, and strains are commonly available and usefu herein, such as Schizosaccharomyces pombe [Beach and Nurse, Nature, 290: 140 (1981 ); E 139,383 published May 2, 1985], Kluyveromyces hosts (U.S. 4,943,529) such as, e.g., K. lactis [Louvencourt et al., J. Bacteriol., 737 (1983)], K. fragilis, K. bulgaricυs, K. thermotolerans, and K. marxianus, yarrowia [EP 402,226], Pichia pastoris [EP 183,070 Sreekrishna etal.. J. Basic Microbiol., 28: 265-278 (1988)], Candida, Trichoderma reesia [E 244,234], Neurospora crassa [Case et al., Proc. Natl. Acad. Sci. USA. 76: 5259-526 (1979)], and filamentous fungi such as, e.g, Neurospora, Penicil/iυm, To/ypoc/adiυm [WO 91/00357 published 10 January 1991], and Aspergillus hosts such as nidulans [Ballance etal.. Biochem. Bioohvs. Res. Commun.. 1 12: 284-289 (1983); Tilburn etal.. Gene, 26: 205- 221 (1983); Yelton et al., Proc. Natl. Acad. Sci. USA. 8J_. 1470-1474 (1984)] and A. nige [Kelly and Hynes, EMBO J., 4: 475-479 (1985)]. Suitable host cells for the expression of glycosylated target polypeptide are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori host cells have been identified. See, e.g., Luckow etal.. Bio/Technology, 6: 47-55 (1988); Miller etal.. in Genetic Engineering. Setlow, J.K. et al., eds.. Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature, 315: 592-594 (1985). A variety of such viral strains are publicly available, e.g., the L-1 variant of Autographa calif ornica NPV and the Bm-5 strain of Bomby mori NPV, and such viruses may be used as the virus herein according to the presen invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell culture of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as host Typically, plant cells are transfected by incubation with certain strains of the bacteriu Agrobacterium tumefaciens, which has been previously manipulated to contain the targe polypeptide DNA. During incubation of the plant cell culture with A. tumefaciens, the DN encoding target polypeptide is transferred to the plant cell host such that it is transfected, an will, under appropriate conditions, express the target polypeptide DNA. In addition, regulator and signal sequences compatible with plant cells are available, such as the nopaline synthas promoter and polyadenylation signal sequences. Depicker et al., J. Mol. Appl. Gen.. ±: 56 (1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gen are capable of activating or increasing transcription levels of plant-expressible genes i recombinant DNA-containing plant tissue. See EP 321 ,196 published 21 June 1989. However, interest has been greatest in vertebrate cells, and propagation of vertebrat cells in culture (tissue culture) has become a routine procedure in recent years fTissue Culture Academic Press, Kruse and Patterson, editors (1973)]. Examples of useful mammalian hos cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651 ); huma embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graha etal., J. Gen Virol.. 36: 59 [1977]); baby hamster kidney cells (BHK, ATCC CCL 10); Chines hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA. 77: 421 [1980]); mouse sertoli cells (TM4, Mather, Biol. Reorod.. 23: 243-251 [1980]); monkey kidne cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587) human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CC 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CC 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATC CCL51 ); TRI cells (Mather et al., Annals N.Y. Acad. Sci.. 383: 44-68 [1982]); MRC 5 cells FS4 cells; and a human hepatoma cell line (Hep G2). Preferred host cells are human embryoni kidney 293 and Chinese hamster ovary cells. Host cells are transfected and preferably transformed with the above-describe expression or cloning vectors of this invention and cultured in conventional nutrient medi modified as appropriate for inducing promoters, selecting transformants, or amplifying th genes encoding the desired sequences. Transfection refers to the taking up of an expression vector by a host cell whether o not any coding sequences are in fact expressed. Numerous methods of transfection are know to the ordinarily skilled artisan, for example, CaP0 4 and electroporation. Successf transfection is generally recognized when any indication of the operation of this vector occu within the host cell. Transformation means introducing DNA into an organism so that the DNA is replicabl either as an extrachromosomal element or by chromosomal integrant. Depending on the ho cell used, transformation is done using standard techniques appropriate to such cells. Th calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook al., supra, is generally used for prokaryotes or other cells that contain substantial cell-wa barriers. Infection with Agrobacterium tumefaciens is used for transformation of certain plan cells, as described by Shaw et al.. Gene, 23: 315 (1983) and WO 89/05859 published 2 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitatio method described in sections 16.30-16.37 of Sambrook et al, supra, is preferred. Genera aspects of mammalian cell host system transformations have been described by Axel in U.S 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried ou according to the method of Van Solingen et al., J. Bact.. 130: 946 (1977) and Hsiao et al. Proc. Natl. Acad. Sci. (USA). 76: 3829 (1979). However, other methods for introducing DN into cells such as by nuclear injection, electroporation, or protoplast fusion may also be used. Culturing the Host Cells Prokaryotic cells used to produce the target polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., supra. The mammalian host cells used to produce the target polypeptide of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ([MEM], Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ([DMEM], Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace, Meth. Enz.. 58: 44 (1979), Barnes and Sato, Anal. Biochem.. 102: 255 (1980), U.S. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Pat. Re. 30,985, may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromol range), and glucose or an equivalent energy source. Any other necessary supplements m also be included at appropriate concentrations that would be known to those skilled in the ar The culture conditions, such as temperature, pH, and the like, are those previously used wi the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. The host cells referred to in this disclosure encompass cells in in vitro culture as w as cells that are within a host animal. It is further envisioned that the target polypeptides of this invention may be produce by homologous recombination, or with recombinant production methods utilizing contr elements introduced into cells already containing DNA encoding the target polypeptid currently in use in the field. For example, a powerful promoter/enhancer element, suppressor, or an exogenous transcription modulatory element is inserted in the genome of t intended host cell in proximity and orientation sufficient to influence the transcription of DN encoding the desired target polypeptide. The control element does not encode the targ polypeptide of this invention, but the DNA is present in the host cell genome. One ne screens for cells making the target polypeptide of this invention, or increased or decrease levels of expression, as desired. Detecting Gene Amplification/Expression Gene amplification and/or expression may be measured in a sample directly, f example, by conventional Southern blotting, northern blotting to quantitate the transcriptio of mRNA (Thomas, Proc. Natl. Acad. Sci. USA. 77: 5201 -5205 [1980]), dot blotting (DN analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequence provided herein. Various labels may be employed, most commonly radioisotopes, particularl 32 P. However, other techniques may also be employed, such as using biotin-modifie nucleotides for introduction into a polynucleotide. The biotin then serves as the site for bindin to avidin or antibodies, which may be labeled with a wide variety of labels, such a radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employe that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RN hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assa may be carried out where the duplex is bound to a surface, so that upon the formation duplex on the surface, the presence of antibody bound to the duplex can be detected. Gene expression, alternatively, may be measured by immunological methods, such a immunohistochemical staining of tissue sections and assay of cell culture or body fluids, t quantitate directly the expression of gene product. With immunohistochemical stainin techniques, a cell sample is prepared, typically by dehydration and fixation, followed b reaction with labeled antibodies specific for the gene product coupled, where the labels ar usually visually detectable, such as enzymatic labels, fluorescent labels, luminescent label and the like. A particularly sensitive staining technique suitable for use in the present inventio is described by Hsu etal., Am. J. Clin. Path.. 75: 734-738 (1980). Antibodies useful for immunohistochemical staining and/or assay of sample fluids ma be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, th antibodies may be prepared against a native target polypeptide or against a synthetic peptid based on the DNA sequences provided herein as described further in Section 4 below. Purification of The Target polypeptide The target polypeptide preferably is recovered from the culture medium as a secrete polypeptide, although it also may be recovered from host cell lysates when directly expresse without a secretory signal. When the target polypeptide is expressed in a recombinant cell other than one of huma origin, the target polypeptide is completely free of proteins or polypeptides of human origin However, it is necessary to purify the target polypeptide from recombinant cell proteins o polypeptides to obtain preparations that are substantially homogeneous as to the targe polypeptide. As a first step, the culture medium or lysate is centrifuged to remove particulat cell debris. The membrane and soluble protein fractions are then separated. The targe polypeptide may then be purified from the soluble protein fraction and from the membrane fraction of the culture lysate, depending on whether the target polypeptide is membrane bound. The following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; and protein A Sepharose columns to remove contaminants such as IgG. Target polypeptide variants in which residues have been deleted, inserted or substituted are recovered in the same fashion, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a target polypeptide fusion with another protein or polypeptide, e.g. a bacterial or viral antigen, facilitates purification; an immunoaffinity column containing antibody to the antigen (or containing antigen, where th target polypeptide is an antibody) can be used to adsorb the fusion. Immunoaffinity column such as a rabbit polyclonal anti-target polypeptide column can be employed to absorb th target polypeptide variant by binding it to at least one remaining immune epitope. A proteas inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibi proteolγtic degradation during purification, and antibiotics may be included to prevent th growth of adventitious contaminants. One skilled in the art will appreciate that purificatio methods suitable for native target polypeptide may require modification to account for change in the character of the target polypeptide or its variants upon expression in recombinant ce culture. Covalent Modifications of Target Polypeptides Covalent modifications of target polypeptides are included within the scope of thi invention. One type of covalent modification included within the scope of this invention is target polypeptide fragment. Target polypeptide fragments having up to about 40 amino aci residues may be conveniently prepared by chemical synthesis, or by enzymatic or chemic cleavage of the full-length target polypeptide or variant target polypeptide. Other types o covalent modifications of the target polypeptide or fragments thereof are introduced into th molecule by reacting specific amino acid residues of the target polypeptide or fragment thereof with an organic derivatizing agent that is capable of reacting with selected side chain or the N- or C-terminal residues. Cysteinyl residues most commonly are reacted with σ-haloacetates (and correspondin amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl o carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction wit bromotrifluoroacetone, σ-bromo- ?-(5-imidozoyl)propionic acid, chloroacetyl phosphate, N alkylmaleimides,3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1 ,3-diazole. Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7. because this agent is relatively specific for the histidyl side chain. Para-bromophenacy bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at p 6.0. Lysinyl and amino terminal residues are reacted with succinic or other carboxylic aci anhydrides. Derivatization with these agents has the effect of reversing the charge of th lysinyl residues. Other suitable reagents for derivatizing σ-amino-containing residues includ imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyze reaction with glyoxylate. Arginyl residues are modified by reaction with one or several conventional reagents among them phenylglyoxal, 2,3-butanedione, 1 ,2-cyclohexanedione, and ninhydrin Derivatization of arginine residues requires that the reaction be performed in alkaline condition because of the high pK a of the guanidine functional group. Furthermore, these reagents ma react with the groups of lysine as well as the arginine epsilon-amino group. The specific modification of tyrosyl residues may be made, with particular interest i introducing spectral labels into tyrosyl residues by reaction with aromatic diazoniu compounds or tetranitromethane. Most commonly, N-acetylimϊdizole and tetranitromethan are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosy residues are iodinated using 125 l or 131 l to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable. Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides (R'-N =C=N-R'), where R and R' are different alkyl groups, such as 1 cyclohexyI-3-(2-morpholinyl-4-ethyl) carbodiimide or 1 -ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginγl and glutaminyl residues by reaction with ammonium ions. Derivatization with bifunctional agents is useful for crosslinking target polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-target polypeptide antibodies, and vice versa. Commonly used crosslinking agents include, e.g., 1 ,1- bis(dϊazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidγlpropionate), and bifunctional maleimides such as bis-N- maleimido-1 ,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]pr opioimi- date yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. 3,969,287; 3,691 ,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization. Glutaminyl and asparaginγl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention. Other modifications include hydroxylation of proline and lysine, phosphorylation o hydroxyl groups of seryl or threonyl residues, methylation of the σ-amino groups of lysin arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecula Properties. W.H. Freeman & Co., San Francisco, pp. 79-86 [1983]), acetylation of the N terminal amine, and amidation of any C-terminal carboxyl group. Another type of covalent modification of the target polypeptide included within th scope of this invention comprises altering the native glycosylation pattern of the polypeptide By altering is meant deleting one or more carbohydrate moieties found in the native targe polypeptide, and/or adding one or more glycosylation sites that are not present in the nativ target polypeptide. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refer to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. Th tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amin acid except proline, are the recognition sequences for enzymatic attachment of th carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tri peptide sequences in a polypeptide creates a potential glycosylation site. O-linke glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5 hydroxyproline or 5-hydroxylysine may also be used. Addition of glycosylation sites to the target polypeptide is conveniently accomplishe by altering the amino acid sequence such that it contains one or more of the above-describe tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made b the addition of, or substitution by, one or more serine or threonine residues to the native targe polypeptide sequence (for O-linked glycosylation sites). For ease, the target polypeptide amin acid sequence is preferably altered through changes at the DNA level, particularly by mutatin the DNA encoding the target polypeptide at preselected bases such that codons are generate that will translate into the desired amino acids. The DNA mutation(s) may be made usin methods described above under the heading of "Amino Acid Sequence Variants of Targe Polypeptide". Another means of increasing the number of carbohydrate moieties on the targe polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Thes procedures are advantageous in that they do not require production of the polypeptide in a hos cell that has glycosylation capabilities for N- and 0- linked glycosylation. Depending on th coupling mode used, the sugar(s) may be attached to (a) arginine and histidine, (b) fre carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl group such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These method are described in WO 87/05330 published 1 1 September 1987, and in Aplin and Wriston (CR Crit. Rev. Biochem.. PP. 259-306 [19811). Removal of carbohydrate moieties present on the native target polypeptide may b accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of th polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. Thi treatment results in the cleavage of most or all sugars except the linking sugar (N acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemica deglycosylation is described by Hakimuddin etal. (Arch. Biochem. Biophvs.. 259:52 [1987] and by Edge et al. (Anal. Biochem.. 1 18:131 [1981 ]). Enzymatic cleavage of carbohydrat moieties on polypeptides can be achieved by the use of a variety of endo- and exo glycosidases as described by Thotakura et al. (Meth. Enzvmol.. 138:350 [1987]). Glycosylation at potential glycosylation sites may be prevented by the use of the compound tunicamycin as described by Duskin et al. (J. Biol. Chem.. 257:3105 [1982]). Tunicamycin blocks the formation of protein-N-glycoside linkages. Another type of covalent modification of the target polypeptide comprises linking the target polypeptide to various nonproteinaceous polymers, e.g. polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S. 4,640,835; 4,496,689; 4,301 ,144; 4,670,417; 4,791 ,192 or 4,179,337. The target polypeptide also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose orgelatin-microcapsulesand poly-[methylmethacylate] microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particfes and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences. 16th edition, Osol, A., Ed., (1980). Target polypeptide preparations are also useful in generating antibodies, for screening for binding partners, as standards in assays for the target polypeptide (e.g. by labeling the target polypeptide for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptor assay), in affinity purification techniques, and in competitive-type receptor binding assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like. Since it is often difficult to predict in advance the characteristics of a variant target polypeptide, it will be appreciated that some screening of the recovered variant will be needed to select the optimal variant. For example, a change in the immunological character of t target polypeptide molecule, such as affinity for a given antigen or antibody, is measured a competitive-type immunoassaγ. The variant is assayed for changes in the suppression enhancement of its activity by comparison to the activity observed for the target polypepti in the same assay. Other Jtential modifications of protein or polypeptide properties such redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, stability recombinant cell culture or in plasma, or the tendency to aggregate with carriers or in multimers are assayed by methods well known in the art. Diagnostic and Related Uses of the Antibodies The antibodies of this invention are useful in diagnostic assays for antigen expressio in specific cells or tissues. The antibodies are detectably labeled and/or are immobilized on insoluble matrix. The antibodies of this invention find further use for the affinity purification of th antigen from recombinant cell culture or natural sources. Suitable diagnostic assays f the antigen and its antibodies depend on the particular antigen or antibody. Generally, suc assays include competitive and sandwich assays, and steric inhibition assays. Competitive an sandwich methods employ a phase-separation step as an integral part of the method whil steric inhibition assays are conducted in a single reaction mixture. Fundamentally, the sam procedures are used for the assay of the antigen and for substances that bind the antige although certain methods will be favored depending upon the molecular weight of th substance being assayed. Therefore, the substance to be tested is referred to herein as a analyte, irrespective of its status otherwise as an antigen or antibody, and proteins that bin to the analyte are denominated binding partners, whether they be antibodies, cell surfac receptors, or antigens. Analytical methods for the antigen or its antibodies all use one or more of the followin reagents: labeled analyte analogue, immobilized analyte analogue, labeled binding partne immobilized binding partner and steric conjugates. The labeled reagents also are known a "tracers." The label used (and this is also useful to label antigen nucleic acid for use as a prob is any detectable functionality that does not interfere with the binding of analyte and it binding partner. Numerous labels are known for use in immunoassay, examples includin moieties that may be detected directly, such as fluorochrome, chemiluminescent, an radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatize to be detected. Examples of such labels include the radϊoisotopes 32 P, C, 125 l, 3 H, and 131 fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and i derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferas (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidas (HRP), alkaline phosphatase, ?-galactosidase, glucoamylase, lysozyme, saccharide oxidase e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme tha employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and th like. Conventional methods are available to bind these labels covalentiy to proteins o polypeptides. For instance, coupling agents such as dialdehydes, carbodiimides, dimaleimides bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with th above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S Pat. Nos. 3,940,475 (fluorimetry) and 3,645,090 (enzymes); Hunter etal.. Nature. 144: 94 (1962): David etal.. Biochemistry. 13: 1014-1021 (1974): Pain etal.. J. Immunol. Methods 40: 219-230 (1981 ); and Nygren, J. Histochem. and Cvtochem.. 30: 407-412 (1982) Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase The conjugation of such label, including the enzymes, to the antibody is a standard manipulative procedure for one of ordinary skill in immunoassay techniques. See, for example O'Sullivan et al., "Methods for the Preparation of Enzyme-antibody Conjugates for Use i Enzyme Immunoassay," in Methods in Enzymology. ed. J.J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, New York, 1981 ), pp. 147-166. Such bonding methods are suitable for use with the antibodies and polypeptides of this invention. immobilization of reagents is required for certain assay methods. Immobilization entails separating the binding partner from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich etal... U.S. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation. Other assay methods, known as competitive or sandwich assays, are well established and widely used in the commercial diagnostics industry. Competitive assays rely on the ability of a tracer analogue to compete with the test sample analyte for a limited number of binding sites on a common binding partner. The binding partner generally is insolubilized before or after the competition and then the tracer and analyt bound to the binding partner are separated from the unbound tracer and analyte. Thi separation is accomplished by decanting (where the binding partner was preinsolubilized) o by centrifuging (where the binding partner was precipitated after the competitive reaction) The amount of test sample analyte is inversely proportional to the amount of bound tracer a measured by the amount of marker substance. Dose-response curves with known amount of analyte are prepared and compared with the test results to quantitatively determine th amount of analyte present in the test sample. These assays are called ELISA systems whe enzymes are used as the detectable markers. Another species of competitive assay, called a "homogeneous" assay, does not requir a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and use such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies th enzyme activity. In this case, the antigen or its immunologically active fragments ar conjugated with a bifunctional organic bridge to an enzyme such as peroxidase. Conjugate are selected for use with antibody so that binding of the antibody inhibits or potentiates th enzyme activity of the label. This method perse is widely practiced under the name of EMIT. Steric conjugates are used in steric hindrance methods for homogeneous assay. Thes conjugates are synthesized by covalently linking a low-molecular-weight hapten to a smal analyte so that antibody to hapten substantially is unable to bind the conjugate at the sam time as anti-analyte. Under this assay procedure the analyte present in the test sample wil bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change i the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is fluorophore. Sandwich assays particularly are useful for the determination of antigen or antibodies In sequential sandwich assays an immobilized binding partner is used to adsorb test sampl analyte, the test sample is removed as by washing, the bound analyte is used to adsorb labele binding partner, and bound material is then separated from residual tracer. The amount o bound tracer is directly proportional to test sample analyte. In "simultaneous" sandwic assays the test sample is not separated before adding the labeled binding partner. A sequentia sandwich assay using an anti-antigen monoclonal antibody as one antibody and a polyclona anti-antigen antibody as the other is useful in testing samples for particular antigen activity The foregoing are merely exemplary diagnostic assays for the import and humanized antibodies of this invention. Other methods now or hereafter developed for the determinatio of these analytes are included within the scope hereof, including the bioassaγs describe above. Immunotoxins This invention is also directed to immunochemical derivatives of the antibodies of thi invention such as immunotoxins (conjugates of the antibody and a cytotoxic moiety) Antibodies which carry the appropriate effector functions, such as with their constan domains, are also used to induce lysis through the natural complement process, and to interac with antibody dependent cytotoxic cells normally present. For example, purified, sterile filtered antibodies are optionally conjugated to a cytotoxi such as ricin for use in AIDS therapy. US Patent Application Serial No. 07/350,895 illustrate methods for making and using immunotoxins for the treatment of HIV infection. The methods of this invention, for example, are suitable for obtaining humanized antibodies for use a immunotoxins for use in AIDS therapy. The cytotoxic moiety of the immunotoxin may be a cytotoxic drug or an enzymatically active toxin of bacterial, fungal, plant or animal origin, or an enzymatically active fragment of such a toxin. Enzymatically active toxins and fragments thereof used are diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrϊn A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. In another embodiment, the antibodies are conjugated to small molecule anticancer drugs such as cis-platin or 5FU. Conjugates of the monoclonal antibody and such cytotoxic moieties are made using a variety of bifunctional protein coupling agents. Examples of such reagents are SPDP, IT , bifunctional derivatives of imidoesters such as dimethyl adipimidate HCl, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine, bis-diazonium derivatives such as bis- (p-diazoniumbenzoyD- -ethylenediamine, diisocyanates such as tolylene 2,6-diϊsocyanate and bis-active fluorine compounds such as 1,5-difluoro- 2,4-dinitrobenzene. The lysing portion of a toxin may be joined to the Fab fragment of the antibodies. Immunotoxins can be made in a variety of ways, as discussed herein. Commonly known crosslinking reagents can be used to yield stable conjugates. Advantageously, monoclonal antibodies specifically binding the domain of the antigen which is exposed on the infected cell surface, are conjugated to ricin A chain. Most advantageously the ricin A chain is degiycosylated and produced through recombinant mean An advantageous method of making the ricin immunotoxin is described in Vitetta et a Science 238:1098 (1987). When used to kill infected human cells in vitro for diagnostic purposes, the conjugat will typically be added to the cell culture medium at a concentration of at least about 10 n The formulation and mode of administration for in vitro use are not critical. Aqueo formulations that are compatible with the culture or perfusion medium will normally be use Cytotoxicity may be read by conventional techniques. Cytotoxic radiopharmaceuticals for treating infected cells may be made by conjugatin radioactive isotopes (e.g. I, Y, Pr) to the antibodies. Advantageously alpha particle-emitti isotopes are used. The term 'cytotoxic moiety" as used herein is intended to include su isotopes. In a preferred embodiment, ricin A chain is degiycosylated or produced witho oligosaccharides, to decrease its clearance by irrelevant clearance mechanisms (e.g., the liver In another embodiment, whole ricin (A chain plus B chain) is conjugated to antibody if t galactose binding property of B-chain can be blocked ("blocked ricin"). In a further embodiment toxin-conjugates are made with Fab or F(ab') 2 fragment Because of their relatively small size these fragments can better penetrate tissue to reac infected cells. In another embodiment, fusogenic liposomes are filled with a cytotoxic drug and th liposomes are coated with antibodies specifically binding the particular antigen. Antibody Dependent Cellular Cytotoxicity Certain aspects of this invention involve antibodies which are (a) directed against particular antigen and (b) belong to a subclass or isotype that is capable of mediating the lysi of cells to which the antibody molecule binds. More specifically, these antibodies shoul belong to a subclass or isotype that, upon complexing with cell surface proteins, activat serum complement and/or mediates antibody dependent cellular cytotoxicity (ADCC) b activating effector cells such as natural killer cells or macrophages. Biological activity of antibodies is known to be determined, to a large extent, by th constant domains or Fc region of the antibody molecule (Uananue and Benacerraf, Textboo of Immunology, 2nd Edition, Williams & Wilkins, p. 218 (1984)). This includes the ' , ability t activate complement and to mediate antibody-dependent cellular cytotoxicity (ADCC) a effected by leukocytes. Antibodies of different classes and subclasses differ in this respec (pO as do antibodies from the same subclass but different species; according to the presen invention, antibodies of those classes having the desired biological activity are prepared Preparation of these antibodies involves the selection of antibody constant domains are thei incorporation in the humanized antibody by known technique. For example, mous immunoglobulins of the lgG3 and lgG2a class are capable of activating serum complemen upon binding to the target cells which express the cognate antigen, and therefore humanize antibodies which incorporate lgG3 and lgG2a effector functions are desirable for certai therapeutic applications. in general, mouse antibodies of the lgG2a and lgG3 subclass and occasionally lgG1 ca mediate ADCC, and antibodies of the lgG3, lgG2a, and IgM subclasses bind and activate seru complement. Complement activation generally requires the binding of at least two Ig molecules in close proximity on the target cell. However, the binding of only one IgM molecul activates serum complement. The ability of any particular antibody to mediate lysis of the target cell by complemen activation and/or ADCC can be assayed. The cells of interest are grown and labeled in vitro; the antibody is added to the cell culture in combination with either serum complement or immune cells which may be activated by the antigen antibody complexes. Cytolysis of the target cells is detected by the release of label from the lysed cells. In fact, antibodies can be screened using the patient's own serum as a source of complement and/or immune cells. The antibody that is capable of activating complement or mediating ADCC in the in vitro test can then be used therapeutically in that particular patient. This invention specifically encompasses consensus Fc antibody domains prepared and used according to the teachings of this invention. Therapeutic and Other Uses of the Antibodies When used in vivo for therapy, the antibodies of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that have desired therapeutic effect). They will normally be administered parenterally. The dose and dosage regimen will depend upon the degree of the infection, the characteristics of the particular antibody or ϊmmunotoxin used, e.g., its therapeutic index, the patient, and the patient's history. Advantageously the antibody or immunotoxin is administered continuously over a period of 1-2 weeks, intravenously to treat cells in the vasculature and subcutaneously and intraperitoneally to treat regional lymph nodes. Optionally, the administration is made during the course of adjunct therapy such as combined cycles of radiation, chemotherapeutic treatment, or administration c. " tumor necrosis factor, interferon or other cytoprotective immunomodulatory agent. For parenteral administration the antibodies will be formulated in a unit dosage injectab form (solution, suspension, emulsion) in association with a pharmaceutically acceptab parenteral vehicle. Such vehicles are inherently nontoxic, and non-therapeutic. Examples such vehicles are water, saline. Ringer's solution, dextrose solution, and 5% human seru albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate can also be used. Liposom may be used as carriers. The vehicle may contain minor amounts of additives such substances that enhance isotonicity and chemical stability, e.g., buffers and preservative The antibodies will typically be formulated in such vehicles at concentrations of about 1 mg/ to 10 mg/ml. Use of IgM antibodies may be preferred for certain applications, however IgG molecul by being smaller may be more able than IgM molecules to localize to certain types of infect cells. There is evidence that complement activation in vivo leads to a variety of biologic effects, including the induction of an inflammatory response and the activation of macrophag (Uananue and Benecerraf, Textbook of Immunology, 2nd Edition, Williams & Wilkins, p. 21 (1984)). The increased vasodilation accompanying inflammation may increase the ability various agents to localize in infected cells. Therefore, antigen-antibody combinations of t type specified by this invention can be used therapeutically in many ways. Additionall purified antigens (Hakomori, Ann. Rev. Immunol. 2:103 (1984)) or anti-idiotypic antibodi (Nepom et al., Proc. Natl. Acad. Sci. 81 :2864 (1985); Koprowski etal., Proc. Natl. Acad. S 81 :216 (1984)) relating to such antigens could be used to induce an active immune respon in human patients. Such a response includes the formation of antibodies capable of activati human complement and mediating ADCC and by such mechanisms cause infected c destruction. Optionally, the antibodies of this invention are useful in passively immunizing patient as exemplified by the administration of humanized anti-HIV antibodies. The antibody compositions used in therapy are formulated and dosages established a fashion consistent with good medical practice taking into account the disorder to be treate the condition of the individual patient, the site of delivery of the composition, the method administration and other factors known to practitioners. The antibody compositions a prepared for administration according to the description of preparation of polypeptides f administration, infra. (, Z Deposit of Materials As described above, cultures of the muMAb4D5 have been deposited with th American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC). This deposit was made under the provisions of the Budapest Treaty on the Internation Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and th Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures for 3 years from the date of the deposit. The organisms will be made available by ATCC under th terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. an ATCC, which assures permanent and unrestricted availability of the progeny of the culture to the public upon issuance of the pertinent U.S. patent or upon laying open to the public o any U.S. or foreign patent application, whichever comes first, and assures availability of th progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitle thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (includin 37 CFR § 1 .12 with particular reference to 886 OG 638). In respect of those designations in which a European patent is sought, a sample of th deposited microorganism will be made available until the publication of the mention of th grant of the European patent or until the date on which the application has been refused o withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an exper nominated by the person requesting the sample. (Rule 28(4) EPC) The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws. The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiments are intended to illustrate only certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that they represent. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the append claims. It is understood that the application of the teachings of the present invention to specific problem or situation will be within the capabilities of one having ordinary skill in t art in light of the teachings contained herein. Examples of the products of the prese invention and representative processes for their isolation, use, and manufacture appear belo but should not be construed to limit the invention. EXAMPLES EXAMPLE 1 . HUMANIZATION OF muMAb4D5 Here we report the chimerization of muMAb4D5 (chMAb4D5) and the rapid an simultaneous humanization of heavy (V H ) and light (V L ) chain variable region genes using novel "gene conversion mutagenesis" strategy. Eight humanized variants (huMAb4D5) wer constructed to probe the importance of several FR residues identified by our molecul modeling or previously proposed to be critical to the conformation of particular CDRs (s Chothia, C. & Lesk, A. M., J. Mol. Biol. 196:901-91 7 (1987); Chothia, C. et al., Natu 342:877-883 (1989); Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)). Efficie transient expression of humanized variants in non-myeloma cells allowed us to rapidl investigate the relationship between binding affinity for p185 HER2 ECD and anti-proliferativ activity against p185 H R2 overexpressing carcinoma cells. MATERIALS and METHODS Cloning of Variable Region Genes. The muMAb4D5 V H and V genes were isolated b polymerase chain reaction (PCR) amplification of mRNA from the corresponding hybridom (Fendly, B. M. et al., Cancer Res. 50:1550-1558 (1990)) as described by Orlandi et a (Orlandi, R. et al., Proc. Natl. Acad. Sci. USA 86:3833-3837 (1989)). Amino termin sequencing of muMAb4D5 V and V H was used to design the sense strand PCR primer whereas the anti-sense PCR primers were based upon consensus sequences of murin framework residues (Orlandi, R. et al., Proc. Natl. Acad. Sci. USA 86:3833-3837 (1989 Kabat, E. A. et al., Sequences of Proteins of Immunological Interest (National Institutes Health, Bethesda, MD, 1987)) incorporating restriction sites for directional cloning shown b u n d e r l i n i n g a n d l i s t e d a f t e r t h e s e q u e n c e s : V s e n s e , 5 ' TCCGATATCCAGCTGACCCAGTCTCCA-3' (SEQ. ID NO. 7), fcoRV; V L anti-sense, 5 GTTTGATCTCCAGCTTGGTACCHSCDCCGAA-3' (SEQ. ID NO. 8), Asp7.8; V H sense, 5 AGGTSMARCTGCAGSAGTCWGG-3' (SEQ. ID NO. 9), Pstl and V H anti-sense, 5 TGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAG-3' (SEQ. ID NO. 10), _?S-EII; where H A or C or T, S = C or G, D = A or G or T, M = A or C, R = A or G and W = A or T. Th PCR products were cloned into pUC1 19 (Vieira, J. & Messing, J., Methods Enzymol. 153:3-1 (1987)) and five clones for each variable domain sequenced by the dideoxy method (Sange F. et al., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977)). Molecular Modelling. Models for muMAb4D5 V H and V domains were constructe separately from consensus coordinates based upon seven Fab structures from the Brookhave protein data bank (entries 1 FB4, 2RHE, 2MCP, 3FAB, 1 FBJ, 2HFL and 1 REI). The Fa fragment KOL (Marquart, M. et al., J. Mol. Biol. 141:369-391 (1980)) was first chosen as template for V L and V H domains and additional structures were then superimposed upon thi structure using their main chain atom coordinates (INSIGHT program, Biosym Technologies) The distance from the template Cσto the analogous Cσ in each of the superimposed structure was calculated for each residue position. If all (or nearly all) Cσ-Cσ distances for a give residue were ≤ 1 A, then that position was included in the consensus structure. In most case the .-sheet framework residues satisfied these criteria whereas the CDR loops did not. Fo each of these selected residues the average coordinates for individual N, Cσ, C, 0 and C atoms were calculated and then corrected for resultant deviations from non-standard bon geometry by 50 cycles of energy minimization using the DISCOVER program (Biosy Technologies) with the AMBER forcefield (Weiner, S. J. et al., J. Amer. Chem. Soc. 106:765-784 (1984)) and Cσ coordinates fixed. The side chains of highly conserved residues, such as the disulfide-bridged cysteine residues, were then incorporated into the resultan consensus structure. Next the sequences of muMAb4D5 V L and V H were incorporated starting with the CDR residues and using the tabulations of CDR conformations from Chothia et al. (Chothia, C. et al., Nature 342:877-883 (1989)) as a guide. Side-chain conformations were chosen on the basis of Fab crystal structures, rotamer libraries (Ponder, J. W. & Richards, F. M., J. Mol. Biol. 193:775-791 (1987)) and packing considerations. Since V H -CDR3 could not be assigned a definite backbone conformation from these criteria, two models were created from a search of similar sized loops using the INSIGHT program. A third model was derived using packing and solvent exposure considerations. Each model was then subjected to 5000 cycles of energy minimization. In humanizing muMAb4D5, consensus human sequences were first derived from the most abundant subclasses in the sequence compilation of Kabat et al. (Kabat, E. A. et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, M 1987)), namely V L K subgroup I and V H group III, and a molecular model generated for thes sequences using the methods described above. A structure for huMAb4D5 was created b transferring the CDRs from the muMAb4D5 model into the consensus human structure. A huMAb4D5 variants contain human replacements of muMAb4D5 residues at three position within CDRs as defined by sequence variability (Kabat, E. A. et al., Sequences of Proteins o Immunological Interest (National Institutes of Health, Bethesda, MD, 1987)) but not as define by structural variability (Chothia, C. & Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)) V L -CDR1 K24R, V L -CDR2 R54L and V L -CDR2 T56S. Differences between muMAb4D5 an the human consensus framework residues (Fig. 1 ) were individually modeled to investigat their possible influence on CDR conformation and/or binding to the p185 HER2 ECD. Construction of Chimeric Genes. Genes encoding chMAb4D5 light and heavy chain were separately assembled in previously described phagemid vectors containing the huma cytomegalovirus enhancer and promoter, a 5' intron and SV40 poiyadenylation signal (Gorman C. M. et al., DNA & Prot. Engin. Tech. 2:3-10 (1990)). Briefly, gene segments encodin muMAb4D5 V (Fig. 1 A) and REI human #*• ■ light chain C (Palm, W. & Hilschmann, N., Physio/. Chem. 356:167-191 (1975)) were precisely joined as were genes for muMAb4D5 V (Fig. 1 B) and human γ1 constant region (Capon, D. J. et al., Nature 337:525-531 (1989)) b simple subcloning (Boyle, A., in Current Protocols in Molecular Biology, Chapter 3 (F. A Ausubel et al., eds., Greene Publishing & Wiley-lnterscience, New York, 1990)) an site-directed mutagenesis (Carter, P., in Mutagenesis: A Practical Approach, Chapter 1 (IR Press, Oxford, UK 1991 )). The Y , isotype was chosen as it has been found to be the preferre human isotype for supporting ADCC and complement dependent cytotoxicity using matche sets of chimeric (Brϋggemann, M. et al., J. Exp. Med. 166:1351 -1361 (1987)) or humanize antibodies (Riechmann, L. etal., Nature 332:323-327 (1988)). The PCR-generated V and V fragments (Fig. 1 ) were subsequently mutagenized so that they faithfully represent th sequence of muMAb4D5 determined at the protein level: V H Q1 E, V V104L and T109 (variants are denoted by the amino acid residue and number followed by the replacemen amino acid). The human y constant regions are identical to those reported by Ellison et al (Ellison, J. W. et al., Nucleic Acids Res. 13:4071 -4079 (1982)) except for the mutation E359D and M361 L (Eu numbering, as in Kabat, E. A. et al., Sequences of Proteins o Immunological Interest (National Institutes of Health, Bethesda, MD, 1987)) which we installe to convert the antibody from the naturally rare A allotype to the much more common non- allotype (Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)). This was an attempt t reduce the risk of anti-allotype antibodies interfering with therapy. Construction of Humanized Genes. Genes encoding chMAb4D5 light chain and hea chain Fd fragment (V H and C H 1 domains) were subcioned together into pUC1 19 (Vieira, J. Messing, J., Methods Enzymol. 153:3-1 1 (1987)) to create pAK1 and simultaneousl humanized in a single step (Fig. 2). Briefly, sets of 6 contiguous oligonucleotides we designed to humanize V H and V L (Fig. 1). These oligonucleotides are 28 to 83 nucleotides i length, contain zero to 19 mismatches to the murine antibody template and are constraine to have 8 or 9 perfectly matched residues at each end to promote efficient annealing an ligation of adjacent oligonucleotides. The sets of V H and V L humanization oligonucleotides ( pmol each) were phosphorylated with either ATP or κ- 32 P-ATP (Carter, P. Methods Enzymo 154:382-403 (1987)) and separately annealed with 3.7 pmol of pAK1 template in 40 μl 1 mM Tris-HCI (pH 8.0) and 10 mM MgCI 2 by cooling from 100 °C to room temperature ove - 30 min. The annealed oligonucleotides were joined by incubation with T4 DNA ligase (1 units; New England Biolabs) in the presence of 2 μl 5 mM ATP and 2 l 0.1 M DTT for 10 mi at 14 °C. After electrophoresis on a 6% acrylamide sequencing gel the assemble oligonucleotides were located by autoradiography and recovered by electroelution. Th assembled oligonucleotides (-0.3 pmol each) were simultaneously annealed to 0.15 pmo single-stranded deoxyuridine-containing pAK1 prepared according to Kunkel et al. (Kunkel, T A. etal., Methods Enzymol. 154:367-382 (1987)) in 10 μl 40 mM Tris-HCI (pH 7.5) and 1 mM MgCI 2 as above. Heterodupiex DNA was constructed by extending the primers with T DNA polymerase and transformed into E. coli BMH 71-18 mυt as previously describe (Carter, P., in Mutagenesis: A Practical Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )) The resultant phagemid DNA pool was enriched first for huV-_ by restriction purification usin Xhol and then for huV H by restriction selection using Stul as described in Carter, P., i Mutagenesis: A Practical Approach, Chapter 1 (IRL Press, Oxford, UK 1991 ); and in Wells J. A. et al., Phil. Trans. R. Soc. Lond. A 317:415-423 (1986). Resultant clones containing both huV L and huV H genes were identified by nucleotide sequencing (Sanger, F. et al., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977)) and designated pAK2. Additional humanized variants were generated by site-directed mutagenesis (Carter, P., in Mutagenesis: A Practica Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )). The muMAb4D5 V L and V H gene segments in the transient expression vectors described above were then precisely replaced with their humanized versions. Expression and Purification of MAb4D5 Variants. Appropriate MAb4D5 light and heavy chain cDNA expression vectors were co-transfected into an adenovirus transformed human embryonic kidney cell line, 293 (Graham, F. L. et al., J. Gen. Virol. 36:59-72 (1977)) using high efficiency procedure (Gorman, C. M. et al., DNA & Prot. Engin. Tech. 2:3-10 (1990) Gorman, C, in DNA Cloning, vol II, pp 143-190 (D. M. Glover, ed., IRL Press, Oxford, U 1985)). Media were harvested daily for up to 5 days and the cells re-fed with serum fre media. Antibodies were recovered from the media and affinity purified on protein A sepharos CL-4B (Pharmacia) as described by the manufacturer. The eluted antibody wa buffer-exchanged into phosphate-buffered saline by G25 gel filtration, concentrated b ultrafiltration (Centriprep-30 or Centricon-100, Amicon), sterile-filtered (Millex-GV, Millipore and stored at 4 °C. The concentration of antibody was determined by using both tota immunoglobulin and antigen binding ELISAs. The standard used was huMAb4D5-5, whos concentration had been determined by amino acid composition analysis. Cell Proliferation Assay. The effect of MAb4D5 variants upon proliferation of th human mammary adenocarcinoma cell line, SK-BR-3, was investigated as previously describe (Fendly, B. M. et al., Cancer Res. 50:1550-1558 (1990)) using saturating MAb4D concentrations. Affinity Measurements. The antigen binding affinity of MAb4D5 variants wa determined using a secreted form of the p185 HER2 ECD prepared as described in Fendly, B M. et al., J. Biol. Resp. Mod. 9:449-455 (1990). Briefly, antibody and p185 HER2 ECD wer incubated in solution until equilibrium was found to be reached. The concentration of fre antibody was then determined by ELISA using immobilized p185 ER2 ECD and used t calculate affinity ( C d ) according to Friguet et al. (Friguet, B. et al., J. Immunol. Method 77:305-319 (1985)). RESULTS Humanization of muMAb4D5. The muMAb4D5 V L and V H gene segments were firs cloned by PCR and sequenced (Fig. 1 ). The variable genes were then simultaneousl humanized by gene conversion mutagenesis using preassembled oligonucleotides (Fig. 2). 31 1 -mer oligonucleotide containing 39 mismatches to the template directed 24 simultaneou amino acid changes required to humanize muMAb4D5 V L . Humanization of muMAb4D5 V required 32 amino acid changes which were installed with a 361 -mer containing 5 mismatches to the muMAb4D5 template. Two out of 8 clones sequenced precisely encod huMAb4D5-5, although one of these clones contained a single nucleotide imperfection. Th 6 other clones were essentially humanized but contained a small number of errors: < nucleotide changes and < 1 single nucleotide deletion per kilobase. Additional humanize variants (Table 3) were constructed by site-directed mutagenesis of huMAb4D5-5. Expression levels of huMAb4D5 variants were in the range of 7 to 15 /g/ml as judge by ELISA using immobilized p185 HER2 ECD. Successive harvests of five 10 cm plates allowe 200 μg to 500 mg of each variant to be produced in a week. Antibodies affinity purified o protein A gave a single band on a Coomassie blue stained SDS poiyacrγlamide gel of mobilit consistent with the expected M τ of - 150 kDa. Electrophoresis under reducing conditions gav 2 bands consistent with the expected M r of free heavy (48 kDa) and light (23 kDa) chains (no shown). Amino terminal sequence analysis (10-cycles) gave the mixed sequence expecte (see Fig. 1) from an equimolar combination of light and heavy chains (not shown). huMAb4D5 Variants. In general, the FR residues were chosen from consensus huma sequences (Kabat, E. A. et al., Sequences of Proteins of Immunological Interest (Nationa Institutes of Health, Bethesda, MD, 1987)) and CDR residues from muMAb4D5. Additiona variants were constructed by replacing selected human residues in huMAb4D5-1 with thei muMAb4D5 counterparts. These are V H residues 71 , 73, 78, 93 plus 102 and V L residue 55 plus 66 identified by our molecular modeling. V H residue 71 has previously been propose by others (Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)) to be critical to th conformation of V H -CDR2. Amino acid sequence differences between huMAb4D5 varian molecules are shown in Table 3, together with their p185 HER2 ECD binding affinity and maximal anti-proliferative activities against SK-BR-3 cells. Very similar K d values wer obtained for binding of MAb4D5 variants to either SK-BR-3 cells or to p185 HER2 ECD (Tabl 3). However, K ά estimates derived from binding of MAb4D5 variants to p185 HER2 ECD wer more reproducible with smaller standard errors and consumed much smaller quantities of antibody than binding measurements with whole cells. The most potent humanized variant designed by molecular modeling, huMAb4D5-8, contains 5 FR residues from muMAb4D5. This antibody binds the p185 HER2 ECD 3-fold more tightly than does muMAb4D5 itself (Table 3) and has comparable anti-proliferative activity with SK-BR-3 cells (Fig. 3). In contrast, huMAb4D5-1 is the most humanized but least potent muMAb4D5 variant, created by simply installing the muMAb4D5 CDRs into the consensus human sequences. huMAb4D5-1 binds the p185 HER2 ECD 80-fold less tightly than does the murine antibody and has no detectable anti-proliferative activity at the highest antibody concentration investigated (16 /.g/ml). The anti-proliferative activity of huMAb4D5 variants against p185 HER2 overexpressing SK-BR-3 ceils is not simply correlated with their binding affinity for the p185 HER2 ECD. For example, installation of three murine residues into the V H domain of huMAb4D5-2 (D73 L78A and A93S) to create huMAb4D5-3 does not change the antigen binding affinity but doe confer significant anti-proliferative activity (Table 3). The importance of V H residue 71 (Tramontano, A. er a/., J. Mol. Biol. 215:175-18 (1990)) is supported by the observed 5-fold increase in affinity for p185 HER2 ECD o replacement of R71 in huMAb4D5-1 with the corresponding murine residue, alanin (huMAb4D5-2). In contrast, replacing V H L78 in huMAb4D5-4 with the murine residu alanine (huMAb4D5-5), does not significantly change the affinity for the pl 85" " * E ECD o change anti-proliferative activity, suggesting that residue 78 is not of critical function significance to huMAb4D5 and its ability to interact properly with the extracellular domain o p 1 85 HER2 V | _ residue 66 is usually a glycine in human and murine K chain sequences (Kabat, E A. et al., Sequences of Proteins of Immunological Interest (National Institutes of Health Bethesda, MD, 1987)) but an arginine occupies this position in the muMAb4D5 k light chain The side chain of residue 66 is likely to affect the conformation of V L -CDR1 and V L -CDR2 an the hairpin turn at 68-69 (Fig. 4). Consistent with the importance of this residue, the mutatio V L G66R (huMAb4D5-3 → huMAb4D5-5) increases the affinity for the p185 HER2 ECD b 4-fold with a concomitant increase in anti-proliferative activity. From molecular modeling it appears that the tyrosyl side chain of muMAb4D5 V residue 55 may either stabilize the conformation of V H -CDR3 or provide an interaction at th V | _-V H interface. The latter function may be dependent upon the presence of V H Y102. In th context of huMAb4D5-5 the mutations V L E55Y (huMAb4D5-6) and V H V102Y (huMAb4D5-7 individually increase the affinity for p185 HER2 ECD by 5-fold and 2-fold respectively, wherea together (huMAb4D5-8) they increase the affinity by 1 1 -fold. This is consistent with eithe proposed role of V L Y55 and V H Y102. Secondary Immune Function of huMAb4D5-8. MuMAb4D5 inhibits the growth o human breast tumor cells which overexpress p185 (Hudziak, R. M. et al., Molec. Cell Biol. 9:1 165-1 172 (1989)). The antibody, however, does not offer the possibility of direc tumor cytotoxic effects. This possibility does arise in huMAb4D5-8 as a result of its hig affinity (K d = 0.1 μM) and its human IgG-- subtype. Table 4 compares the ADCC mediate by huMAb4D5-8 with muMAb4D5 on a normal lung epithelial cell line, WI-38, which expresse a low level of p185 HER2 and on SK-BR-3, which expresses a high level of p185 HER2 . Th results demonstrate that: (1 ) huMAb4D5 has a greatly enhanced ability to carry out ADCC a compared with its murine parent; and (2) that this activity may be selective for cell type which overexpress p185 π ■" -" • --. DISCUSSION MuMAb4D5 is potentially useful for human therapy since it is cytostatic toward human breast and ovarian tumor lines overexpressing the -£ ?2-encoded p185 receptor-like tyrosine kinase. Since both breast and ovarian carcinomas are chronic disease it is anticipated that the optimal MAb4D5 variant molecule for therapy will have low immunogenicity and will be cytotoxic rather than solely cytostatic in effect. Humanization o muMAb4D5 should accomplish these goals. We have identified 5 different huMAb4D5 variants which bind tightly to p185 HER2 ECD (K d ≤ 1 nM) and which have significant anti-proliferative activity (Table 3). Furthermore huMAb4D5-8 but not muMAb4D5 mediates ADCC against human tumor cell lines overexpressing p185 ER2 in the presence of human effector cells (Table 4) as anticipated for a human γ1 isotype (Brϋggemann, M. etal., J. Exp. Med. 166:1351-1361 (1987); Riechmann, L. et al., Nature 332:323-327 (1988)). Rapid humanization of huMAb4D5 was facilitated by the gene conversion mutagenesis strategy developed here using long preassembled oligonucleotides. This method requires less than half the amount of synthetic DNA as does total gene synthesis and does not require convenient restriction sites in the target DNA. Our method appears to be simpler and more reliable than a variant protocol recently reported (Rostapshov, V. M. et al., FEBS Lett 249:379-382 (1989)). Transient expression of huMAb4D5 in human embryonic kidney 293 cells permitted the isolation of a few hundred micrograms of huMAb4D5 variants for rapid characterization by growth inhibition and antigen binding affinity assays. Furthermore, different combinations of light and heavy chain were readily tested by co-transfection of corresponding cDNA expression vectors. The crucial role of molecular modeling in the humanization of muMAb4D5 is illustrated by the designed variant huMAb4D5-8 which binds the p185 HER2 ECD 250-fold more tightly than the simple CDR loop swap variant, huMAb4D5-1. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riechmann, L. etal., Nature 332:323-327 (1988); Queen, C. etal., Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989)). Here we have extended this earlier work by others with a designed humanized antibody which binds its antigen 3-fold more tightly than the parent rodent antibody. While this result is gratifying, assessment of the success of the molecular modeling must await the outcome of X-ray structure determination. From analysis of huMAb4D5 variants (Table 3) it is apparent that their anti-proliferative activity is not a simple function of their binding affinity for p185 HER2 ECD. For example the huMAb4D5- variant binds p185 HER2 3-fold more tightly than muMAb4D5 but the humanized variant slightly less potent in blocking the proliferation of SK-BR-3 cells. Additional huMAb4D variants are currently being constructed in an attempt to identify residues triggering t anti-proliferative activity and in an attempt to enhance this activity. In addition to retaining tight receptor binding and the ability to inhibit cell growth, t huMAb4D5-8 also confers a secondary immune function (ADCC). This allows for dire cytotoxic activity of the humanized molecule in the presence of human effector cells. T apparent selectivity of the cytotoxic activity for cell types which overexpress p185 HER2 allo for the evolution of a straightforward clinic approach to those human cancers characteriz by overexpression of the HER2 protooncogene. 11 Table 3. p185 HER2 ECD binding affinity and anti-proliferative activities of MAb4D5 variants V H Residue * V L Residue * MAb4D5 71 73 78 93 102 55 66 d + Relative cell Variant R3 FR3 FR3 R3 CDR3 CDR2 FR3 nM proliferation* huMAb4D5-l R D L A V E G 25 102 _-uMAb4D5-2 Ala D L A V E G 4.7 101 huMAb4D5-3 Ala Thr Ala Ser V E G 4.4 66 uMAb4D5-4 Ala Thr L Ser V E Arg 0.82 56 huMAb4D5-5 Ala Thr Ala Ser V E Arg 1.1 48 huMAb4D5-6 Ala Thr Ala Ser V Tyr Arg 0.22 51 huMAb4D5-7 Ala Thr Ala Ser Tyr E Arg 0.62 53 uMAb4D5-8 Ala Thr Ala Ser Tyr Tyr Arg 0.10 54 muMAb4D5 Ala Thr Ala Ser Tyr Tyr Arg 0.30 37 Human and murine residues are shown in one letter and three letter amino acid code respectively. i A_ d values for the p185 HER2 ECD were determined using the method of Friguet et al. (43) and the standard error of each estimate is ≤ ± 10%. * Proliferation of SK-BR-3 cells incubated for 96 hr with MAb4D5 variants shown as a percentage of the untreated control as described (Hudziak, R. M. et al., Molec. Cell. Biol. 9:1 165-1 172 (1989)). Data represent the maximal anti-proliferative effect for each variant (see Fig. 3A) calculated as the mean of triplicate determinations at a MAb4D5 concentration of 8 //g/ml. Data are all taken from the same experiment with an estimated standard error of ≤ ± 15%. Tabfe 4. Selectivity of antibody dependent tumor cell cytotoxicity mediated by huMAb4D5-8 I-38 * SK-BR-3 Effector:Target ratio + muMAb4D5 huMAb4D5-8 muMAb4D5 huMAb4D5-8 * Sensitivity to ADCC of two human cell lines (W 1-38, normal lung epithelium; and SK-BR-3, human breast tumor cell line) are compared. WI-38 expresses a low level of p185 HER2 (0.6 pg per μg cell protein) and SK-BR-3 expresses a high level of p185 ER2 (64 pg pi 85 HER2 per μg cell protein), as determined by ELISA (Fendly etal., J. Biol. Resp. Mod. 9:449-455 (1990)). t ADCC assays were carried out as described in Brϋggemann et al., J. Exp. Med. 166:1351-1361 (1987). Effector to target ratios were of IL-2 activated human peripheral blood lymphocytes to either WI-38 fibroblasts or SK-BR-3 tumor cells in 96-well microtiter plates for 4 hours at 37 °C. Values given represent percent specific cell lysis as determined by Cr release. Estimated standard error in these quadruplicate determinations was __ ± 10%. * Monoclonal antibody concentrations used were 0.1 //g/ml (A) and 0.1 /g/ml (B). EXAMPLE 2. Schematic Method for Humanizing an Antibody Seouence This example illustrates one stepwise elaboration of the methods for creating a humanized sequence described above. It will be understood that not all of these steps are essential to the claimed invention, and that steps may be taken in different order. 1. ascertain a consensus human variable domain amino acid sequence and prepare from it a consensus structural model. 2. prepare model of import (the non-human domain to be humanized) variable domain sequences and note structural differences with respect to consensus human model. 3. identify CDR sequences in human and in import, both by using Kabat (supra, 1987) and crystal structure criteria. If there is any difference in CDR identity from the different criteria, use of crystal structure definition of the CDR, but retain the Kabat residues as important framework residues to import. 4. substitute import CDR sequences for human CDR sequences to obtain initial "humanized" sequence. 5. compare import non-CDR variable domain sequence to the humanized sequence and note divergences. 6. Proceed through the following analysis for each amino acid residue where the import diverges from the humanized. a. If the humanized residue represents a residue which is generally highly conserved across all species, use the residue in the humanized sequence. If the residue is not conserved across all species, proceed with the analysis described in 6b. b. If the residue is not generally conserved across all species, ask if the residue is generally conserved in humans. i. If the residue is generally conserved in humans but the import residue differs, examine the structural models of the import and human sequences and determine if the import residue would be likely to affect the binding or biological activity of the CDRs by considering 1 ) could it bind antigen directly and 2) could it affect the conformation of the CDR. If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, leave the humanized residue unchanged. ii. If the residue is also not generally conserved in humans, examine the structural models of the import and human sequences and determine if the import residue would be likely to affect the binding or biological activity of the CDRs be considering 1 ) could it bind antigen directly and 2) could it affect the conformation of the CDR. If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, proceed to the next step. a) Examine the structural models of the import and human sequences and determine if the residue is exposed on the surface of the domain or is buried within. If the residue is exposed, use the residue in the humanized sequence. If the residue is buried, proceed to the next step. (i) Examine the structural models of the import and human sequences and determine if the residue is likely to affect the V L - V H interface. Residues involved with the interface include: 34L, 36L, 38L, 43L, 33L, 36L, 85L, 87L, 89L, 91 L, 96L, 98L, 35H, 37H, 39H, 43H, 45H, 47H, 60H, 91 H, 93H, 95H, 100H, and 103H. If no effect is likely, use the residue in the humanized sequence. If some affect is likely, substitute the import residue. 7. Search the import sequence, the consensus sequence and the humanized sequence for glycosylation sites outside the CDRs, and determine if this glycosylation site is likely to have any affect on antigen binding and/or biological activity. If no effect is likely, use the human sequence at that site; if some affect is likely, eliminate the glycosylation site or use the import sequence at that site. 8. After completing the above analysis, determine the planned humanized sequence and prepare and test a sample. If the sample does not bind well to the target antigen, examine the particular residues listed below, regardless of the question of residue identity between the import and humanized residues. a. Examine particular peripheral (non-CDR) variable domain residues that may, due to their position, possibly interact directly with a macromolecular antigen, including the following residues (where the * indicates residues which have been found to interact with antigen based on crystal structures): i. Variable light domain: 36, 46, 49 * , 63-70 ii. Variable heavy domain: 2, 47 * . 68, 70, 73-76. b. Examine particular variable domain residues which could interact with, or otherwise affect, the conformation of variable domain CDRs, including the following (not including CDR residues themselves, since it is assumed that, because the CDRs interact with one another, any residue in one CDR could potentially affect the conformation of another CDR residue) (L= LIGHT, H = HEAVY, residues appearing in bold are indicated to be structurally important according the Chothia et al., Nature 342:877 (1989), and residues appearing in italic were altered during humanization by Queen etal. (PDL), Proc. Natl. Acad. Sci. USA 86:10029 (1989) and Proc. Natl. Acad. Sci. USA 88:2869 (1991 ).): i. Variable light domain: a) CDR-1 (residues 24L-34L): 2L, 4L, 66L-69L, 71 L b) CDR-2 (residues 50L-56L): 35L, 46L, 47L, 48L, 49L, 58L, 62L, 64L-66L, 71 L, 73L c) CDR-3 (residues 89L-97L): 2L, 4L, 36L, 98L, 37H, 45H, 47H, 58H, 60H ii. Variable heavy domain: a) CDR-1 (residues 26H-35H): 2H, 4H, 24H, 36H, 71 H, 73H, 76H, 78H, 92H, 94H b) CDR-2 (residues 50H-55H): 49H, 69H, 69H, 71 H, 73H, 78H c) CDR-3 (residues 95H-102H): examine all residues as possible interaction partners with this loop, because this loop varies in size and conformation much more than the other CDRs. 9. If after step 8 the humanized variable domain still is lacking in desired binding, repeat step 8. In addition, re-investigate any buried residues which might affect the V L - V H interface (but which would not directly affect CDR conformation). Additionally, evaluate the accessibility of non-CDR residues to solvent. EXAMPLE 3. Engineering a Humanized Bispecific F(ab')o Fragment This example demonstrates the construction of a humanized bispecific antibody (BsF(ab') 2 v1 by separate E. coli expression of each Fab' arm followed by directed chemical coupling in vitro. BsF(ab') 2 v1 (anti-CD3 / anti-p185 HER2 ) was demonstrated to retarget the cytotoxic activity of human CD3 + CTL in vitro against the human breast tumor cell line, SK-BR-3, which overexpresses the p185 HER2 product of the protooncogene HER2. This example demonstrates the minimaiistic humanization strategy of installing as few murine residues as possible into a human antibody in order to recruit antigen-binding affinity and biological properties comparable to that of the murine parent antibody. This strategy proved very successful for the anti- p185 HER2 arm of BsF(ab') 2 v1. In contrast BsF(ab') 2 v1 binds to T cells via its anti-CD3 arm much less efficiently than does the chimeric BsF(ab') 2 which contains the variable domains of the murine parent anti-CD3 antibody. Here we have constructed additional BsF(ab') 2 fragments containing variant anti- CD3 arms with selected murine residues restored in an attempt to improve antibody binding to T cells. One such variant, Bs F(ab') 2 v9, was created by replacing six residues in the second hypervariable loop of the anti-CD3 heavy chain variable domain of BsF(ab') 2 v1 with their counterparts from the murine parent anti-CD3 antibody. BsF(ab') 2 v9 binds to T cells (Jurkat) much more efficiently than does BsF(ab') 2 v1 and almost as efficiently as the chimeric BsF(ab') 2 . This improvement in the efficiency of T cell binding of the humanized BsF(ab') 2 is an important step in its development as a potential therapeutic agent for the treatment of p185 HER2 -overexpressing cancers. Bispecific antibodies (BsAbs) with specificities for tumor-associated antigens and surface markers on immune effector cells have proved effective for retargeting effector cells to kill tumor targets both in vitro and in vivo (reviewed by Fanger, M. W. et al., Immunol. Today 10: 92-99 (1989); Fanger, M. W. et al., Immunol. Today 12: 51-54 (1991 ); and Nelson, H., Cancer Cells 3: 163-172 (1991 )). BsF(ab') 2 fragments have often been used in preference to intact BsAbs in retargeted cellular cytotoxicity to avoid the risk of killing innocent bystander cells binding to the Fc region of the antibody. An additional advantage of BsF(ab') 2 over intact BsAbs is that they are generally much simpler to prepare free of contaminating monospecific molecules (reviewed by Songsivilai, S. and Lachmann, P. J., Clin. Exp. Immunol. 79: 315-321 (1990) and Nolan, O. and O'Kennedy, R., Biochim. Biophys. Ada 1040: 1 -1 1 (1990)). BsF(ab') 2 fragments are traditionally constructed by directed chemical coupling of Fab' fragments obtained by limited proteolysis plus mild reduction of the parent rodent monoclonal Ab (Brennan, M. etal.. Science 229, 81-83 (1985) and Glennie, M. J. etaL. J. Immunol. 139: 2367-2375 (1987)). One such BsF(ab') 2 fragment (anti-glioma associated antigen / anti-CD3) was found to have clinical efficacy in glioma patients (Nitta, T. etal., Lancet 335: 368-371 (1990) and another BsF(ab') 2 (anti-indium chelate / anti- carcinoembryonic antigen) allowed clinical imaging of colorectal carcinoma (Stickney, D. R. et al. , Antibody, Immunoconj. Radiopharm. 2: 1-13 (1989)). Future BsF(ab') 2 destined for clinical applications are likely to be constructed from antibodies which are either human or at least "humanized" (Riechmann, L. etal., Nature 332: 323-327 (1988) to reduce their immunogenicity (Hale, G. etal., Lancet i: 1394-1399 (1988)). Recently a facile route to a fully humanized BsF(ab') 2 fragment designed for tumor immunotherapy has been demonstrated (Shalaby, M. R. et al., J. Exp. Med. 175: 217-225 (1992)). This approach involves separate £ coli expression of each Fab' arm followed by traditional directed chemical coupling in vitro to form the BsF(ab') 2 . One arm of the BsF(ab') 2 was a humanized version (Carter, P. etal., Proc. Natl. Acad. Sci. USA (1992a) and Carter, P., et al., Bio Technology 10: 163-167 (1992b)) of the murine monoclonal Ab 4D5 which is directed against the p185 HER2 product of the protooncogene HER2 (c-erbB-2) (Fendly, B. M. etal.. Cancer Res. 50: 1550- 1558 (1989)). The humanization of the antibody 4D5 is shown in Example 1 of this application. The second arm was a minimalistically humanized anti- CD3 antibody (Shalaby etal. supra) which was created by installing the CDR loops from the variable domains of the murine parent monoclonal Ab UCHT1 (Beverley, P. C. L. and Callard, R. E., Eur. J. Immunol. 11: 329-334 (1981)) into the humanized anti-p185 HER2 antibody. The BsF(ab') 2 fragment containing the most potent humanized anti-CD3 variant (v1 ) was demonstrated by flow cytometry to bind specifically to a tumor target overexpressing p185 HEB2 and to human peripheral blood mononuclear cells carrying CD3. In addition, Bs F(ab' ) 2 v1 enhanced the cytotoxic effects of activated human CTL 4-fold against SK-BR-3 tumor cells overexpressing p185 HER2 . The example descries efforts to improve the antigen binding affinity of the humanized anti-CD 3 arm by the judicious recruitment of a small number of additional murine residues into the minimalistically humanized anti-CD3 variable domains. MATERIALS AND METHODS Construction of mutations in the anti-CD3 variable region genes. The construction of genes encoding humanized anti-CD3 variant 1 (v1 ) variable light (V L ) and heavy (V H ) chain domains in phagemid pUC1 19 has been described (Shalaby et al. supra). Additional anti-CD3 variants were generated using an efficient site-directed mutagenesis method (Carter, P., Mutagenesis: a practical approach, (M. J. McPherson, Ed.), Chapter 1 , IRL Press, Oxford, UK (1991 )) using mismatched oligonucleotides which either install or remove unique restriction sites. Oligonucleotides used are listed below using lowercase to indicate the targeted mutations. Corresponding coding changes are denoted by the starting amino acid in one letter code followed by the residue numbered according to Kabat, E. A. etal., Sequences of Proteins of Immunological Interest, 5 ,h edition. National Institutes of Health, Bethesda, MD, USA (1991 ), then the replacement amino acid and finally the identity of the anti-CD3 variant: HX1 1 , 5' GTAGATAAATCCtctAACACAGCCTAtCTGCAAATG 3' (SEQ.ID. NO. 1 1 ) V H K75S, v6; HX12, 5' GTAGATAAATCCAAAtctACAGCCTAtCTGCAAATG 3' (SEQ.ID. NO. 12) V H N76S, v7; HX13, 5' GTAGATAAATCCtcttctACAGCCTAtCTGCAAATG 3' (SEQ.ID. NO. 13) V H K75S:N76S, v8; X14, 5' CTTATAAAGGTGTTtCcACCTATaaCcAgAaatTCAA GGatCGTTTCACgATAtcCGTAGATAAATCC 3' (SEQ.ID.NO. 14) V H T57S:A60N:D61 Q:S62K:V63F:G65D, v9; LX6, 5' CTATACCTCCCGTCTgcatTCTGGAGTCCC 3' (SEQ.ID. NO. 15) 9Z V L E55H, v1 1. Oligonucleotides HX1 1 , HX12 and HX13 each remove a site for BspMI, whereas LX6 removes a site for Xhol and HX14 installs a site for EcoRV (bold). Anti-CD3 variant v10 was constructed from v9 by site-directed mutagenesis using oligonucleotide HX13. Mutants were verified by dideoxynucleotide sequencing (Sanger, F. etal., Proc. Natl. Acad. Sci. USA 74: 5463-5467 (1977)). £. coli expression of Fab' fragments The expression plasmid, pAK19, for the co-secretion of light chain and heavy chain Fd' fragment of the most preferred humanized anti-p185 HER2 variant, HuMAb4D5-8, is described in Carter etal., 1992b, supra. Briefly, the Fab' expression unit is bicistronic with both chains under the transcriptional control of the phoA promoter. Genes encoding humanized V L and V H domains are precisely fused on their 5' side to a gene segment encoding the heat-stable enterotoxin II signal sequence and on their 3' side to human k, C L and IgGI C H 1 constant domain genes, respectively. The C H 1 gene is immediately followed by a sequence encoding the hinge sequence CysAlaAla and followed by a bacteriophage λ t 0 transcriptional terminator. Fab' expression plasmids for chimeric and humanized anti-CD3 variants (v1 to v4, Shalaby etal..supra; v6 to vi 2, this study) were created from pAK19 by precisely replacing anti-p185 HER2 V L and V H gene segments with those encoding murine and corresponding humanized variants of the anti-CD3 antibody, respectively, by sub-cloning and site-directed mutagenesis. The Fab' expression plasmid for the most potent humanized anti-CD3 variant identified in this study (v9) is designated pAK22. The anti-p185 HER2 Fab' fragment was secreted from £ coli K12 strain 25F2 containing plasmid pAK19 grown for 32 to 40 hr at 37 * C in an aerated 10 liter fermentor. The final cell density was 120-150 OD S50 and the titer of soluble and functional anti-p185 HER2 Fab' was 1 -2 g/Iiter as judged by antigen binding ELISA (Carter et al., 1992b, supra). Anti-CD3 Fab' variants were secreted from £ coli containing corresponding expression plasmids using very similar fermentation protocols. The highest expression titers of chimeric and humanized anti-CD3 variants were 200 mg/liter and 700 mg/liter, respectively, as judged by total immunoglobulin ELISA. Construction of BsF(ab') 2 fragments Fab' fragments were directly recovered from £ co// ' fermentation pastes in the free thiol form (Fab'-SH) by affinity purification on Streptococcal protein G at pH 5 in the presence of EDTA (Carter et al., 1992b supra). Thioether linked BsF(ab') 2 fragments (anti-p185 HER2 / anti-CD3) were constructed by the procedure of Glennie et al. supra with the following modifications. Anti-p185 HER2 Fab'-SH in 100 mM Tris acetate, 5 mM EDTA (pH 5.0) was reacted with 0.1 vol of 40 mM N,N'-1 ,2-phenylenedimalemide (o-PDM) in dimethyl formamide for - 1 .5 hr at 20 * C. Excess o-PDM was removed by protein G purification of the Fab' maleimide derivative (Fab'-mal) followed by buffer exchange into 20 mM sodium acetate, 5 mM EDTA (pH 5.3) (coupling buffer) using centriprep-30 concentrators (Amicon). The total concentration of Fab' variants was estimated from the measured absorbance at 280 nm (HuMAb4D5-8 Fab' e 0 1 * = 1 .56, Carter et al.. 1992b, supra). The free thiol content of Fab' preparations was estimated by reaction with 5, 5'-dithiobis(2-nitrobenzoic acid) as described by Creighton, T. E., Protein structure: a practical approach, (T. E. Creighton, Ed.), Chapter 7, IRL Press, Oxford, UK (1990). Equimolar amounts of anti-p185 HER2 Fab'-mal (assuming quantitative reaction of Fab'-SH with o-PDM) and each anti-CD3 Fab'-SH variant were coupled together at a combined concentration of 1 to 2.5 mg/ml in the coupling buffer for 14 to 48 hr at 4 * C. The coupling reaction was adjusted to 4 mM cysteine at pH 7.0 and incubated for 15 min at 20 * C to reduce any unwanted disulfide-linked F(ab' ) 2 formed. These reduction conditions are sufficient to reduce inter-heavy chain disulfide bonds with virtually no reduction of the disulfide between light and heavy chains. Any free thiols generated were then blocked with 50 mM iodoacetamide. BsF(ab') 2 was isolated from the coupling reaction by S100-HR (Pharmacia) size exclusion chromatography (2.5 cm x 100 cm) in the presence of PBS. The BsF(ab') 2 samples were passed through a 0.2 mm filter flash frozen in liquid nitrogen and stored at -70 * C. Flow cytometric analysis of Flab' ) 2 binding to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Culture Collection (Rockville, MD) (ATCC TIB 152) and grown as recommended by the ATCC. Aliquots of 10 β Jurkat cells were incubated with appropriate concentrations of BsF(ab') 2 (anti-p185 HER2 / anti- CD3 variant) or control mono-specific anti-p185 HER2 F(ab') 2 in PBS plus 0.1 % (w/v) bovine serum albumin and 10 mM sodium azide for 45 min at 4 * C. The cells were washed and then incubated with fluorescein-conjugated goat anti-human F(ab') 2 (Organon Teknika, West Chester, PA) for 45 min at 4 * C. Cells were washed and analyzed on a FACScan * (Becton Dickinson and Co., Mountain View, CA). Cells (8 x 10 3 ) were acquired by list mode and gated by forward light scatter versus side light scatter excluding dead cells and debris. RESULTS Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, vi, differs from the murine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V L and at 37 out of 122 positions within V H (Shalaby et al., supra) 1992). Here we recruited back additional murine residues into anti- CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional murine residues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were originally kept as human sequences in our minimalistic humanization regime. Thus human residues in V H CDR2 of anti-CD3 v1 were replaced en bloc with t h e i r m u r i n e c o u n t e r p a rt s t o g i v e a n t i - C D 3 v 9 : T57S:A60N:D61 Q:S62K:V63F:G65D (Fig. 5). Similarly, the human residue E55 in V L CDR2 of anti-CD3 v1 was replaced with histidine from the murine anti-CD3 antibody to generate anti-CD3 v1 1. In addition, V H framework region (FR) residues 75 and 76 in anti-CD3 v1 were also replaced with their murine counterparts to create anti-CD3 v8: K75S:N76S. V H residues 75 and 76 are located in a loop close to V H CDR1 and CDR2 and therefore might influence antigen binding. Additional variants created by combining mutations at these three sites are described below. Preparation of BsF(ab') 2 fragments Soluble and functional anti-p185 HER2 and anti-CD3 Fab' fragments were recovered directly from corresponding £ coli fermentation pastes with the single hinge cysteine predominantly in the free thiol form (75-100 % Fab'- SH) by affinity purification on Streptococcal protein G at pH 5 in the presence of EDTA (Carter et al., 1992b, supra). Thioether-linked BsF(ab') 2 fragments were then constructed by directed coupling using o-PDM as described by Glennie ef al., supra. One arm was always the most potent humanized anti-p185 HER2 variant, HuMAb4D5-8 (Carter etal., 1992a, supra) and the other either a chimeric or humanized variant of the anti-CD3 antibody. Anti-p185 HER2 Fab'-SH was reacted with o-PDM to form the maleimide derivative (Fab'-mal) and then coupled to the Fab'-SH for each anti-CD3 variant. F(ab') 2 was then purified away from unreacted Fab' by size exclusion chromatography as shown for a representative preparation (BsF(ab') 2 v8) in data not shown. The F(ab') 2 fragment represents - 54% of the total amount of antibody fragments (by mass) as judged by integration of the chromatograph peaks. SDS-PAGE analysis of this BsF(ab') 2 v8 preparation under non-reducing conditions gave one major band with the expected mobility (M, - 96 kD) as well as several very minor bands (data not shown). Amino-terminal sequence analysis of the major band after electroblotting on to polyvinylidene difiuoride membrane Matsudaira, P., J. Biol. Chem. 262: 10035-10038 (1987) gave the expected mixed sequence from a stoichiometric 1 :1 mixture of light and heavy chains (V L / V H : D/E, l/V, Q/Q, M/L, T/V, Q/E, S/S) expected for BsF(ab') 2 . The amino terminal region of both light chains are identical as are both heavy chains and correspond to consensus human FR sequences. We have previously demonstrated that F(ab') 2 constructed by directed chemical coupling carry both anti-p185 HER2 and anti-CD3 antigen specificities (Shalaby etal., supra). The level of contamination of the BsF(ab') 2 with monospecific F(ab' ) 2 is likely to be very low since mock coupling reactions with either anti- pi 85 HER2 Fab'-mal or anti-CD3 Fab'-SH alone did not yield detectable quantities of F(ab' ) 2 . Furthermore the coupling reaction was subjected to a mild reduction step followed by alkylation to remove trace amounts of disulfide-linked F(ab' ) 2 that might be present. SDS-PAGE of the purified F(ab' ) 2 under reducing conditions gave two major bands with electrophoretic mobility and amino terminal sequence anticipated for free light chain and thioether-Iinked heavy chain dimers. Scanning LASER densitometry of a o-PDM coupled F(ab') 2 preparation suggest that the minor species together represent - 10% of the protein. These minor contaminants were characterized by amino terminal sequence analysis and were tentatively identified on the basis of stoichiometr y of light and heavy chain sequences and their electrophoretic mobility (data not shown). These data are consistent with the minor contaminants including imperfect F(ab' ) 2 in which the disulfide bond between light and heavy chains is missing in one or both arms, trace amounts of Fab' and heavy chain thioether-Iinked to light chain. Binding of BsF(ab') 2 to Jurkat cells Binding of BsF(ab') 2 containing different anti-CD3 variants to Jurkat cells (human acute T cell leukemia) was investigated by flow cytometry (data not shown). BsF(ab') 2 v9 binds much more efficiently to Jurkat cells than does our starting molecule, BsF(ab') 2 v1 , and almost as efficiently as the chimeric BsF(ab') 2 . Installation of additional murine residues into anti-CD3 v9 to create v10 (V H K75S:N76S) and v12 (V H K75S:N76S plus V L E55H) did not further improve binding of corresponding BsF(ab') 2 to Jurkat cells. Nor did recruitment of these murine residues into anti-CD3 v1 improve Jurkat binding: V H K75S (v6), V H 76S (v7), V H K75S:N76S (v8), V L E55H (v1 1) (not shown). BsF(ab') 2 v9 was chosen for future study since it is amongst the most efficient variants in binding to Jurkat cells and contains fewest murine residues in the humanized anti-CD3 arm. A monospecific anti- p185 HER2 F(ab' ) 2 did not show significant binding to Jurkat cells consistent with the interaction being mediated through the anti-CD3 arm. DISCUSSION A minimalistic strategy was chosen to humanize the anti-p185 HER2 (Carter etal., 1992a, supra) and anti-CD3 arms (Shalaby et al., supra) of the BsF(ab') 2 in this study in an attempt to minimize the potential immunogenicity of the resulting humanized antibody in the clinic. Thus we tried to install the minimum number of murine CDR and FR residues into the context of consensus human variable domain sequences as required to recruit antigen- binding affinity and biological properties comparable to the murine parent antibody. Molecular modeling was used firstly to predict the murine FR residues which might be important to antigen binding and secondly to predict the murine CDR residues that might not be required. A small number of humanized variants were then constructed to test these predictions. Our humanization strategy was very successful for the anti-p185 HER2 antibody where one out of eight humanized variants (HuMAb4D5-8, IgGD was identified that bound the p185 HER2 antigen - 3-fold more tightly than the parent murine antibody (Carter etal., 1992a, supra). HuMAb4D5-8 contains a total of five murine FR residues and nine murine CDR residues, including V H CDR2 residues 60-65, were discarded in favor of human counterparts. In contrast, BsF(ab') 2 v1 containing the most potent humanized anti-CD3 variant out of four originally constructed (Shalaby etal., supra) binds J6 cells with an affinity (K ά ) of 140 nM which is - 70-fold weaker than that of the corresponding chimeric BsF(ab') 2 . Here we have restored T cell binding of the humanized anti-CD3 close to that of the chimeric variant by replacing six human residues in V H CDR2 with their murine counterparts: T57S:A60N:D61 Q:S62K:V63F:G65D (anti- CD3 v9, Fig. 5). it appears more likely that these murine residues enhance antigen binding indirectly by influencing the conformation of residues in the N-terminal part of V H CDR2 rather than by directly contacting antigen. Firstly, only N-terminal residues in V H CDR2 (50-58) have been found to contact antigen in one or more of eight crystallographic structures of antibody/antigen complexes (Kabat et al., supra; and Mian, I. S. et al., J. Mol. Biol. 217: 133-1 51 (1991 ), Fig. 5). Secondly, molecular modeling suggests that residues in the C-terminal part of V H CDR2 are at least partially buried (Fig. 5). BsF(ab') 2 v9 binds to SK-BR-3 breast tumor cells with equal efficiency to BsF(ab') 2 v1 and chimeric BsF(ab') 2 as anticipated since the anti- pi 85 HER2 arm is identical in all of these molecules (Shalaby et al., supra, not shown). Our novel approach to the construction of BsF(ab') 2 fragments exploits an £ coli expression system which secretes humanized Fab' fragments at gram per liter titers and permits their direct recovery as Fab'-SH (Carter et al., 1992b, supra). Traditional directed chemical coupling of Fab'-SH fragments is then used to form BsF(ab') 2 />7 vitro (Brennan etal..supra; and Glennie et al., supra). This route to Fab'-SH obviates problems which are inherent in their generation from intact antibodies: differences in susceptibility to proteoiysis and nonspecific cleavage resulting in heterogeneity, low yield as well as partial reduction that is not completely selective for the hinge disulfide bonds. The strategy of using £ co//-derived Fab'-SH containing a single hinge cysteine abolishes some sources of heterogeneity in BsF(ab') 2 preparation such as intra-hinge disulfide formation and contamination with intact parent antibody whilst greatly diminishes others, eg. formation of F(ab' ) 3 fragments. BsF(ab')2 fragments constructed here were thioether-Iinked as originally described by Glennie et al., supra with future in vivo testing of these molecules in mind. Thioether bonds, unlike disulfide bonds, are not susceptible to cleavage by trace amounts of thiol, which led to the proposal that thioether-Iinked F(ab' ) 2 may be more stable than disulfide-linked F(ab' ) 2 in vivo (Glennie et al., supra). This hypothesis is supported by our preliminary pharmacokinetic experiments in normal mice which suggest that thioether-Iinked BsF(ab') 2 vi has a 3- fold longer plasma residence time than BsF(ab') 2 v1 linked by a single disulfide bond. Disulfide and thioether-Iinked chimeric BsF(ab') 2 were found to be indistinguishable in their efficiency of cell binding and in their retargeting of CTL cytotoxicity, which suggests that o- PDM directed coupling does not compromise binding of the BsF(ab') 2 to either antigen (not shown). Nevertheless the nature of the linkage appears not to be critical since a disulfide-linked BsF(ab') 2 (murine anti-p185 HER2 / murine anti-CD3) was recently shown by others (Nishimura et al.. Int. J. Cancer 50: 800-804 (1992) to have potent anti-tumor activity in nude mice. Our previous study (Shalaby etal., supra) together with this one and that of Nishimura, T. et al., supra improve the potential for using BsF(ab') 2 in targeted immunotherapy of p185 HER -overexpressing cancers in humans. EXAMPLE 4. Humanization of an anti-CD 18 antibody A murine antibody directed against the leukocyte adhesion receptor β- chain (known as the H52 antibody) was humanized following the methods described above. Figures 6A and 6B provide amino acid sequence comparisons for the murine and humanized antibody light chains and heavy chains. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Genentech, Inc. (ii) TITLE OF INVENTION: Immunoglobulin Variants (iii) NUMBER OF SEQUENCES: 25 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc. (B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94080 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 07/715272 (B) APPLICATION DATE: 14-JUN-1991 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Adler, Carolyn R. (B) REGISTRATION NUMBER: 32,324 (C) REFERENCE/DOCKET NUMBER: 709P1 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415/225-2614 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID N0:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 109 .amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:1: Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp Val Asn 20 25 30 Thr Ala Val Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 35 40 45 Leu Leu He Tyr Ser Ala Ser Phe Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr He 65 70 75 Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 80 85 90 His Tyr Thr Thr Pro Pro Thr Phe Gly Gin Gly Thr Lys Val Glu 95 100 105 He Lys Arg Thr 109 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn He Lys 20 25 30 Asp Thr Tyr He His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Arg He Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 50 55 60 Ala Asp Ser Val Lys Gly Arg Phe Thr He Ser Ala Asp Thr Ser 65 70 75 Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 100 105 Ala Met Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 110 115 120 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 109 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp Val Ser 20 25 30 Ser Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 35 40 45 Leu Leu He Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He 65 70 75 Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 80 85 90 Tyr Asn Ser Leu Pro Tyr Thr Phe Gly Gin Gly Thr Lys Val Glu 95 100 105 He Lys Arg Thr 109 (2) INFORMATION FOR SEQ ID N0:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4: Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 20 25 30 Asp Tyr Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Val He Ser Glu Asn Gly Gly Tyr Thr Arg Tyr 50 55 60 Ala Asp Ser Val Lys Gly Arg Phe Thr He Ser Ala Asp Thr Ser 65 70 75 Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 100 105 Ala Met Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 110 115 120 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 109 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Asp He Val Met Thr Gin Ser His Lys Phe Met Ser Thr Ser Val 1 5 10 15 Gly Asp Arg Val Ser He Thr Cys Lys Ala Ser Gin Asp Val Asn 20 25 30 Thr Ala Val Ala Trp Tyr Gin Gin Lys Pro Gly His Ser Pro Lys 35 40 45 Leu Leu He Tyr Ser Ala Ser Phe Arg Tyr Thr Gly Val Pro Asp 50 55 60 Arg Phe Thr Gly Asn Arg Ser Gly Thr Asp Phe Thr Phe Thr He 65 70 75 Ser Ser Val Gin Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gin Gin 80 85 90 His Tyr Thr Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu 95 100 105 He Lys Arg Ala 109 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Glu Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly 1 5 10 15 Ala Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn He Lys 20 25 30 Asp Thr Tyr He His Trp Val Lys Gin Arg Pro Glu Gin Gly Leu 35 40 45 Glu Trp He Gly Arg He Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 50 55 60 Asp Pro Lys Phe Gin Asp Lys Ala Thr He Thr Ala Asp Thr Ser 65 70 75 Ser Asn Thr Ala Tyr Leu Gin Val Ser Arg Leu Thr Ser Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 100 105 Ala Met Asp Tyr Trp Gly Gin Gly Ala Ser Val Thr Val Ser Ser 110 115 120 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7: TCCGATATCC AGCTGACCCA GTCTCCA 27 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GTTTGATCTC CAGCTTGGTA CCXXCXCCGA A 31 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: AGGTXXAXCT GCAGXAGTCX GG 22 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: TGAGGAGACG GTGACCGTGG TCCCTTGGCC CCAG 34 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GTAGATAAAT CCTCTAACAC AGCCTATCTG CAAATG 36 i (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GTAGATAAAT CCAAATCTAC AGCCTATCTG CAAATG 36 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: GTAGATAAAT CCTCTTCTAC AGCCTATCTG CAAATG 36 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 68 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: CTTATAAAGG TGTTTCCACC TATAACCAGA AATTCAAGGA TCGTTTCACG 50 ATATCCGTAG ATAAATCC 68 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: CTATACCTCC CGTCTGCATT CTGGAGTCCC 30 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Asp He Gin Met Thr Gin Thr Thr Ser Ser Leu Ser Ala Ser Leu 1 5 10 15 Gly Asp Arg Val Thr He Ser Cys Arg Ala Ser Gin Asp He Arg 20 25 30 Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Asp Gly Thr Val Lys 35 40 45 Leu Leu He Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser 50 55 60 Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr He 65 70 75 Ser Asn Leu Glu Gin Glu Asp He Ala Thr Tyr Phe Cys Gin Gin 80 85 90 Gly Asn Thr Leu Pro Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu 95 100 105 He Lys 107 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID.NO:17: Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp He Arg 20 25 30 Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 35 40 45 Leu Leu He Tyr Tyr Thr Ser Arg Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr He 65 70 75 Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 80 85 90 Gly Asn Thr Leu Pro Trp Thr Phe Gly Gin Gly Thr Lys Val Glu 95 100 105 He Lys 107 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Ser He Ser 20 25 30 Asn Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 35 40 45 Leu Leu He Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr He 65 70 75 Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 80 85 90 Tyr Asn Ser Leu Pro Trp Thr Phe Gly Gin Gly Thr Lys Val Glu 95 100 105 He Lys 107 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Glu Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly 1 5 10 15 Ala Ser Met Lys He Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr 20 25 30 Gly Tyr Thr Met Asn Trp Val Lys Gin Ser His Gly Lys Asn Leu 35 40 45 Glu Trp Met Gly Leu He Asn Pro Tyr Lys Gly Val Ser Thr Tyr 50 55 60 Asn Gin Lys Phe Lys Asp Arg Phe Thr He Ser Lys Ala Thr Leu 65 70 75 Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Leu Met Glu Leu Leu 80 85 90 Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg 95 100 105 Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val Trp Gly 110 115 120 Ala Gly Thr Thr Val Thr Val Ser Ser 125 129 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr 20 25 30 Gly Tyr Thr Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Leu He Asn Pro Tyr Lys Gly Val Ser Thr Tyr 50 55 60 Asn Gin Lys Phe Lys Asp Arg Phe Thr He Ser Val Asp Lys Ser 65 70 75 Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Ser 95 100 105 Asp Trp Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val 110 115 120 Ser Ser 122 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 20 25 30 Ser Tyr Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ser Val He Ser Gly Asp Gly Gly Ser Thr Tyr Tyr 50 55 60 Ala Asp Ser Val Lys Gly Arg Phe Thr He Ser Arg Asp Asn Ser 65 70 75 Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Val Gly Tyr Ser Leu 95 100 105 Ser Gly Leu Tyr Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val 110 115 120 Ser Ser 122 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 454 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Gin Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly 1 5 10 15 Ala Ser Val Lys He Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr 20 25 30 Glu Tyr Thr Met His Trp Met Lys Gin Ser His Gly Lys Ser Leu 35 40 45 Glu Trp He Gly Gly Phe Asn Pro Lys Asn Gly Gly Ser Ser His 50 55 60 Asn Gin Arg Phe Met Asp Lys Ala Thr Leu Ala Val Asp Lys Ser 65 70 75 Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp 80 85 90 Ser Gly He Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly 95 100 105 Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val 110 115 120 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 125 130 135 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 140 145 150 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 155 160 165 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 170 175 180 Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 185 190 195 Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr He Cys Asn Val Asn 200 205 210 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 215 220 225 (© " 2- Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 230 235 240 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255 Asp Thr Leu Met He Ser Arg Thr Pro Glu Val Thr Cys Val Val 260 265 270 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 275 280 285 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 290 295 300 Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 305 310 315 Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 320 325 330 Ser Asn Lys Ala Leu Pro Ala Pro He Glu Lys Thr He Ser Lys 335 340 345 Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro 350 355 360 Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 365 370 375 Val Lys Gly Phe Tyr Pro Ser Asp He Ala Val Glu Trp Glu Ser 380 385 390 Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 395 400 405 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 410 415 420 Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 425 430 435 His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 440 445 450 Ser Pro Gly Lys 454 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 557 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: His His Gin Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys 1 5 10 15 Pro Gly Ala Ser Val Lys He Ser Cys Lys Thr Ser Gly Tyr Thr 20 25 30 Phe Thr Glu Met Gly Trp Ser Cys He He Leu Phe Leu Val Ala 35 40 45 Thr Ala Thr Gly Val His Ser Glu Val Gin Leu Val Glu Ser Gly 50 55 60 Gly Gly Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 65 70 75 Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Arg 80 85 90 Gin Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly He Asn Pro 95 100 105 Lys Asn Gly Gly Thr Ser His Asn Gin Arg Phe Met Asp Arg Phe 110 115 120 Thr He Ser Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Gin Met 125 130 135 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 140 145 150 Trp Arg Gly Leu Asn Tyr Gly Phe Asp Val Arg Tyr Phe Asp Val 155 160 165 Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 170 175 180 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser 185 190 195 Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 200 205 210 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly 215 220 225 Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser 230 235 240 Leu Ser Ser Val Val Thr Val Thr Ser Ser Asn Phe Gly Thr Gin 245 250 255 Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val 260 265 270 Asp Lys Thr Val Glu Arg Lys Cys Cys Val Thr Cys Pro Pro Cys 275 280 285 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 290 295 300 Pro Lys Pro Lys Asp Thr Leu Met He Ser Arg Thr Pro Glu Val 305 310 315 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 320 325 330 Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val 335 340 345 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met He Ser Arg 350 355 360 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 365 370 375 Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Met Glu Val His 380 385 390 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe 395 400 405 Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu Asn 410 415 420 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala 425 430 435 Pro He Glu Lys Thr He Ser Lys Thr Lys Gly Gin Pro Arg Glu 440 445 450 Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 455 460 465 Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 470 475 480 Asp He Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 485 490 495 Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe 500 505 510 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 515 520 525 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 530 535 540 Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 545 550 555 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 214 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Asp Val Gin Met Thr Gin Thr Thr Ser Ser Leu Ser Ala Ser Leu 1 5 10 15 Gly Asp Arg Val Thr He Asn Cys Arg Ala Ser Gin Asp He Asn 20 25 30 Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Asn Gly Thr Val Lys 35 40 45 Leu Leu He Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr He 65 70 75 Ser Asn Leu Asp Gin Glu Asp He Ala Thr Tyr Phe Cys Gin Gin 80 85 90 Gly Asn Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu 95 100 105 He Lys Arg Thr Val Ala Ala Pro Ser Val Phe He Phe Pro Pro 110 115 120 Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130 135 Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val 140 145 150 Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu Ser Val Thr Glu 155 160 165 Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 170 175 180 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 185 190 195 [ Ok Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205 210 Arg Gly Glu Cys 214 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 233 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Met Gly Trp Ser Cys He He Leu Phe Leu Val Ala Thr Ala Thr 1 5 10 15 Gly Val His Ser Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu 20 25 30 Ser Ala Ser Val Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser 35 40 45 Gin Asp He Asn Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly 50 55 60 Lys Ala Pro Lys Leu Leu He Tyr Tyr Thr Ser Thr Leu His Ser 65 70 75 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr 80 85 90 Thr Leu Thr He Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr 95 100 105 Tyr Cys Gin Gin Gly Asn Thr Leu Pro Pro Thr Phe Gly Gin Gly 110 115 120 Thr Lys Val Glu He Lys Arg Thr Val Ala Ala Pro Ser Val Phe 125 130 135 He Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser 140 145 150 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 155 160 165 Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 170 175 180 Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 185 190 195 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 200 205 210 Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr 215 220 225 Lys Ser Phe Asn Arg Gly Glu Cys 230 233

Claims: CLAIMS WE CLAIM: 1. A method for making a humanized antibody comprising amino acid sequence of a non-human, import antibody and a human antibody, comprising the steps of: a. obtaining the amino acid sequences of at least a portion of an import variable domain and of a consensus human variable domain; b. identifying Complementarity Determining Region (CDR) amino acid sequences in the import and the human amino variable domain sequences; c. substituting an import CDR amino acid sequence for the corresponding human CDR amino acid sequence; d. aligning the amino acid sequences of a Framework Region (FR) of the import antibody and the corresponding FR of the consensus antibody; e. identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues; f . determining if the non-homologous import amino acid residue is reasonably expected to have at least one of the following effects: 1. non-covalently binds antigen directly, 2. interacts with a CDR; or 3. participates in the V L - V H interface; and g. for any non-homologous import antibody amino acid residue which is reasonably expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody FR sequence. 2. The method of claim 1 , having an additional step of determining if any such non-homologous residues are exposed on the surface of the domain or buried within it, and if the residue is exposed, retaining the consensus residue. 3. The method of claim 1 , having the additional steps of searching the import variable domain sequence for glycosylation sites, determining if any such glycosylation site is reasonably expected to affect the antigen binding or affinity of the antibody, and if so, substituting the glycosylation site into the consensus sequence. 4. The method of claim 1 , having the additional steps of searching the consensus variable domain sequence for glycosylation sites which are not present at the corresponding amino acid in the import sequence, and if the glycosylation site is not present in the import sequence, substituting the import amino acid residues for the amino acid residues comprising the consensus glycosylation site. 5. The method of claim 1 , having an additional step which comprises aligning import antibody and consensus antibody FR sequences, identifying import antibody FR residues which are non-homologous with the aligned consensus FR sequence, and for each such non- homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site. 6. The method of claim 1 , wherein the corresponding consensus antibody residues are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H, 92H, 93H, and 103H. A method comprising providing at least a portion of an import, non- human antibody variable domain amino acid sequence having a CDR and a FR, obtaining the amino acid sequence of at least a portion of a consensus human antibody variable domain having a CDR and a FR, substituting the non-human CDR for the human CDR in the consensus human antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites: 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H, 92H, 93H, and 103H. 8. The method of claim 7, wherein the substituted residue is the residue found at the corresponding location of the non-human antibody. 9. The method of claim 1 or 7, wherein the consensus human variable domain is a consensus based on human variable domains and additionally variable domains from species other than human. 10. A humanized antibody variable domain having a non-human CDR incorporated into a human antibody variable domain, wherein the improvement comprises substituting an amino acid residue for the human residue at a site selected from the group consisting of: 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H, 92H, 93H, and 103H. 11. The humanized antibody variable domain of claim 10, wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR was obtained. 12. The humanized antibody variable domain of claim 10, wherein no human FR residue other than those set forth in the group has been substituted. 13. A polypeptide comprising the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLI YSASFLESGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTF GQGTKVEIKRT 14. A polypeptide comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWV ARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYC SRWGGDGFYAMDVWGQGTLVTVSS 15. A method for engineering a humanized antibody comprising introducing amino acid residues from an import antibody variable domain into an amino acid sequence representing a consensus of mammalian antibody variable domain sequences. 16. A computer comprising the sequence data of the following amino acid sequence: a. DIQMTQSPSSLSASVGDRVTITCRASQDVSSYLAWYQQKPGKA PKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QYNSLPYTFGQGTKVEIKRT, or b. EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGK GLEWVAVISENGGYTRYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS ' 17. A computer representation of the following amino acid sequence: a. DIQMTQSPSSLSASVGDRVTITCRASQDVSSYLAWYQQKPGKA PKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QYNSLPYTFGQGTKVEIKRT, or b. EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGK GLEWVAVISENGGYTRYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS 18. A method comprising storing a computer representation of the following amino acid sequence: a. DIQMTQSPSSLSASVGDRVTITCRASQDVSSYLAWYQQKPGKA PKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QYNSLPYTFGQGTKVEIKRT, or b. EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGK GLEWVAVISENGGYTRYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS

Inventors: CARTER PAUL J, PRESTA LEONARD G, CARTER, PAUL, J., PRESTA, LEONARD, G.
Applicants: GENENTECH INC, GENENTECH, INC.
Application year: 1992
Main classification: G06F15
IPC codes: A61K38, A61K39, A61P35, C07K14, C07K16, C07K19, C12N15, C12P21, C12R1, G06F15